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In this study, silencing of West Nile virus (WNV) by a plasmid-based shRNA 
expression system was investigated. This plasmid pSilencerTM allows the continuous 
expression of shRNA with the option of selecting and maintaining the positively- 
transfected cells. In addition, this plasmid does not appear to induce cell cytotoxicity in 
the cultured cells. There are only a few criteria available for designing siRNA and the 
precise mechanism of how the siRNA work against its target is still unknown. Hence, it 
was necessary to design several siRNAs against different target sites on the WNV 
genome before choosing the best knock-down site. Four target sites (Capsid, NS2B, 
NS4B and NS5) were selected for the sequence specific disruption via the RNAi 
pathway.  
The first phase of the study was to investigate the efficacy of the various vector 
constructs (targeting different viral genes) in inhibiting WNV replication with transient 
transfection of the plasmids. It was found pshCapsid and pshNS2B had greater silencing 
capability than pshNS4B and pshNS5-1. The former two vectors showed about 2 log10 
unit reduction in virus production when compared to the non-transfected WNV-infected 
cells. The vector pshNS4B showed silencing of WNV only in the first 12 h of infection 
whereas pshNS5-1 could inhibit virus replication for at most 1 log10 unit reduction in 
virus titre.  
As all the vector constructs did not completely inhibit virus production, it was 
suspected that the non-transfected cells allowed WNV to enter and replicate in them. The 
next phase of the study was to select for positively-transfected cells to create stable cell 
lines expressing shRNAs continuously. The cells stably transfected with pshCapsid gave 
the best silencing effect among the four stable cell lines with more than 3 log10 unit 
Summary 
 x
reduction in virus production when compared to the non-transfected WNV-infected cells. 
However, cells stably-transfected with pshNS2B and pshNS4B did not show an enhanced 
reduction in virus titer. Unexpectedly, the shRNA in cells stably-transfected with pshNS5 
(targeting the same site as pshNS5-1) were not able to inhibit WNV replication at both 
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1.0 LITERATURE REVIEW  
 
1.1 FLAVIVIRUS WEST NILE   
 
West Nile virus (WNV) is a mosquito-borne virus that belongs to the family 
Flaviviridae, genus Flavivirus. The virus was first isolated from a febrile female patient 
in the West Nile region of Uganda in 1937 (Smithburn et al., 1940). Based on cross-
neutralisation tests, WNV has been classified within the Japanese encephalitis antigenic-
complex and is closely related to Japanese encephalitis virus (JEV), Murray Valley 
encephalitis virus, St. Louis encephalitis virus and Kunjin virus (Calisher et al., 1989; 
Campbell et al., 2002).   
The WNV isolates have been grouped into two genetic lineages (1 and 2) based on 
the amino acid substitutions and deletions at various positions in their envelope protein 
(Berthet et al., 1997). Lineage 1 isolates have a global distribution and are associated 
with human diseases while lineage 2 viruses are mainly confined to Africa causing 
endemic enzootic infections and occasional mild human disease (Jia et al., 1999; 
Campbell et al., 2002; Lanciotti et al., 2002).  
 
1.2 VIRAL MORPHOLOGY 
 
Mature virus particles are spherical with a diameter of about 50 nm (Figure 1.1a) and 
contain a nucleocapsid of about 25 - 30 nm in diameter. On the surface of the virions are 
5 - 10 nm long projections with terminal knobs of 2 nm diameter (Murphy, 1980). Three 
structural proteins comprise the mature virus particle; namely the large envelope 
glycoprotein (E), a single nucleocaspid protein (C) and the lipid membrane protein [(M) 
(Figure 1.1b)]. The C proteins interact with the positive-sense, single stranded genomic 
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viral RNA to form an icosahedral structure (Figure 1.1c). This is known as the 
nucleocapsid. The M and E proteins are type 1 integral membrane proteins and are 
inserted in the lipid bilayers that are derived from the host cell membranes (endoplasmic 
reticula or plasma membrane). This forms the envelope of the virus particle and 
surrounds the nucleocapsid with little or no association between them. The virus contains 
about 9% carbohydrate by weight, with their composition and structure varying betweent 
vertebrate to arthropod host cells. Several N-linked glycosylation sites are located in the 
prM and E proteins (Brinton, 2002). 
 





Figure 1.1 Structure of mosquito-borne flavivirus. (A) 17 Å structure of WNV 
determined by cryo-EM. A surface shaded view of the virus with one asymmetric unit of  
the icosahedron shown by the triangle. The 5-fold and 3-fold icosahedral symmetry axes 
are labelled (Mukhopadhyay et al., 2003).  (B) Central cross-section showing the cryo-
electron microscopy density.  The outermost layer in dark blue is the envelope protein, 
light blue region is the membrane protein, the green region is the lipid bilayer, the yellow 
region is the nucleocapsid and the red shaded region is the viral RNA (Kuhn et al., 2002).  
(C) Stereo diagram showing the less ordered nucleocapsid in yellow and the viral RNA 







1.3 RNA GENOME ORGANISATION  
 
The single-stranded genome of WNV is approximately 11,029 bases in length and 
contains a single open reading frame (ORF) of 10,301 bases (Rice et al., 1985). Flanking 
the ORF are the 5 and 3 untranslated region (UTR) of the viral genome RNA which are 
96 and 631 nucleotides long, respectively. Within the 3 UTR are two to three conserved 
repeated sequences that form a pseudo-knot structure necessary for RNA cyclization (Shi 
et al., 1996). The positive sense RNA has a type I cap at its 5' end (m7GpppAmp) and 
internal base-methylated adenine residues.  The 5' cap is followed by conserved 
dinucleotide sequence AG. The 3 end terminates with the conserved dinucleotide CUOH 
(Brinton et al., 1986). The single ORF of WNV genome encodes for 3 structural and 7 
non-structural (NS) proteins.   The order of the proteins encoded in the long ORF is 5'-C-
prM/M-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3' with the three structural proteins 
encoded in the 5 quarter and the non-structural proteins encoded within the 3 segment 















The translation of the viral proteins is initiated near the 5 end of the genome and 
the encoded polypeptide is co- and post-translationally processed by viral and cellular 
proteases into the 10 individual proteins (Chambers et al., 1990). Protein C, the first 
structural protein of the ORF, participates in RNA and protein interaction during 
nucleocapsid assembly (Boulton and Westaway, 1972; Wengler & Wengler, 1989). In 
addition, the C protein has been shown to localize to the nucleus during virus infection 
for an unknown reason. It has been postulated that protein C is involved in the 
pathogenesis of WNV infection (Yang et al., 2002). 
  The second structural protein is the precursor membrane (prM) protein. The N-
terminal portion of prM is cleaved in the trans-Golgi network by cellular furin or a 
related protease to produce mature virions with M protein (Stadler et al., 1997). The M 
protein is also believed to be involved the pathogenesis of dengue infections by activating 
mitochondrial apoptotic pathway in different cell lines (Catteau et al., 2003).   
The E protein is the third structural protein and lays on the virus envelope surface, 
conferring a dimeric, anti-parallel orientation. The ectodomain of each monomer of the E 
protein is folded into three distinct domains: a central domain I, an elongated 
dimerization region designated as domain II and domain III having an immunoglobulin-
like modules (Rey et al., 1995).  The E protein plays important roles in virion assembly, 
cell receptor recognition and fusion with cell endosomal membranes. In addition it also 
causes agglutination of red blood cells and induction of the host immune response 
(Gollins and Porterfield, 1985; Chamber et al., 1990; Guirakhoo et al., 1990). 
The NS proteins include the large, highly conserved proteins NS1, NS3, and NS5, 
and four small hydrophobic proteins, NS2A, NS2B, NS4A and NS4B. They are involved 
in the intracellular viral RNA synthesis and replication of WNV. The majority of the NS 
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proteins is multifunctional and interacts with cellular proteins to facilitate the virus 
replication processes.  
NS1 protein gets translocated into the lumen of the endoplasmic reticulum (ER) 
and is cleaved off from NS2A protein by a membrane bound protease (Falgout and 
Markoff, 1995). It is thought to play a crucial role in flavivirus RNA synthesis 
(Lindenbach and Rice, 1999).  In addition, NS1 protein is secreted by the infected cells 
and may play a role in inducing immune response in the host (Macdonald et al., 2005; 
Young et al., 2000).   
The small hydrophobic proteins NS2A, NS2B, NS4A and NS4B contain no 
conserved motifs characteristics of any currently known enzymes. These proteins are 
believed to facilitate the assembly of the viral replication complex and its localization on 
cytoplasmic membranes (Brinton, 2002).  
  The NS3 protein is a serine protease (Bazan and Fletterick, 1989; Gorbalenya et 
al., 1989) and it requires the presence of NS2B protein to be active (Arias et al., 1993). 
NS3 protease cleaves the anchor region from the C protein and other multiple sites within 
the non-structural polyprotein. NS3 protein also has the activities of RNA triphosphatase, 
helicase and NTPase (Wengler and Wengler, 1993; Borowski et al., 2001) which are 
important in the unwinding, replication and capping of the genome (Kapoor et al., 1995). 
The NS5 protein is the largest and the most conserved of the flavivirus proteins 
(Lindenbach and Rice, 2001). The N-terminal region is an S-adenosyl-methionine (SAM) 
transferase domain, involved in the methylation of the type I cap (Koonin, 1993) whilst 





1.4 GENOME REPLICATION STRATEGY 
The virus enters the host cell by clathrin-mediated endocytosis triggered by an 
internalization signal in the cytoplasmic tail of the receptor. Under low pH condition, the 
viral membrane fuses with the endosomal membrane and allows the nucleocapsid to be 
released into the cytoplasm where the RNA genome translocates to the ribosomes for 
translation (Heinz and Allison, 2000; Chu and Ng, 2004). In the cytoplasm, the formation 
of the replication complex (RC) takes place. The NS4A protein binds to the membrane 
site of replication and interacts with both NS1 (in the lumen of ER) via its hydrophilic 
extensions and NS2A proteins. Hydrophobic NS2A, acting like an adaptor, binds to 
another two sites; the terminal loop of 3 UTR and the NS3 protein. In turn, NS3 protein 
interacts with the noncomplementable regions of NS5 protein during translation in cis. 
Upon the completion of RC assembly and its attachment to the ER membrane, cyclization 
of the positive-strand RNA template occurs thus facilitating the switch from translation to 
transcription. In addition, the attachment of RC to the membrane protects itself from 
other cellular processing (Westaway et al., 2002). 
Complementary negative strand viral RNA is synthesized by the viral RNA-
dependent RNA polymerase, NS5 protein, together with other virus NS proteins and 
possibly some cellular proteins. These negative-stranded molecules then serve as 
templates to produce more copies of the positivesense genomic RNA. Replicative form 
(RF) consisting of both positive and negative strands of RNA can serve as templates for 
the synthesis of more genomic RNA through a semi-conservative replication mechanism. 
The RF can bind to the membrane associated RC and initiate the formation of replicative 
intermediates (Westaway et al., 2002).  
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It is noted that the synthesis of viral genomic RNA is approximately 10 times more 
efficient than the minus-strand RNA synthesis. One minus-strand RNA can be copied 
from the plus strand template at a time (replicative form), while multiple copies of the 
positive-sense RNA can be copied from a single negative strand template [(replicative 
intermediate) (Chu and Westaway (1985)]. The nascent genomic RNA can function as 
templates for translation and transcription and as substrates for encapsidation (Westaway 
et al., 1999).  
 
1.5 WEST NILE VIRUS TRANSMISSION CYCLE AND PATHOPHYSIOLOGY 
OF WEST NILE FEVER 
This flavivirus is transmitted via a bird-mosquito-bird cycle (Figure 1.3) where the 
birds act as the amplifying host and mosquitoes as the vector (Gould and Fikrig, 2004). 
West Nile virus has been isolated from Culex, Aedes, Minomyia, Mansonia and 
Anopheles mosquitoes with the Culex species being the most susceptible to infection 
(Ilkal et al., 1997). A number of wild birds have been found to carry high viral load. At 
viremic levels of 105 PFU/ml in the serum, the virus can be maintained in the birds for 
several days to weeks and this amount is enough to infect the feeding mosquitoes. This 
has allowed the birds to be the main reservoir host for maintaining the transmissible 
WNV pool (Bernard and Kramer, 2001). In addition, WNV can be maintained in the 
natural environment by vertical transmission in the Culex mosquitoes and biological 
transmission by ticks (Miller et al., 2000; Lawrie et al., 2004). Many experts also 
believed that WNV might spread to newer areas in the years to come by viremic 
migrating birds. Human, mammals and amphibians are incidental hosts and do not 
contribute to the spread of the virus due to presence of low viral load in the blood 
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(Anderson et al., 1999; Hubalek, 2000; Rappole et al., 2000). However, other modes of 
transmission between human can occur through blood transfusions, organ transplantation 
and even ingestion of breast milk (Hayes and OLeary, 2004).   
 
 
Figure 1.3 Transmission cycle of West Nile Virus (Huhn et al., 2003) 
 
    West Nile virus is the aetiological agent of West Nile fever (Watson et al., 2004). The 
incubation period of WNV infection is usually 2 to 6 days before the presentation of the 
acute non-specific flu-like symptoms like high fever, headache, anorexia, malaise and 
retro-orbital pain (Goldblum et al., 1954; Nur et al., 1999). More than 50 percent of the 
patients develop maculopapular or pale roseolar rash and this appears to be more 
common among children (Petersen and Roehrig, 2001). Myocarditis, pancreatitis and 
hepatitis have also been occasionally described in patients with severe infection (Hayes, 
1988). Being neuroinvasive, WNV can enter and replicate in the central nervous system 
leading to severe neurological disease (Hayes, 2005). Symptoms that arise from WNV 
neuroinvasion are similar to those caused by other flaviviruses, such as Japanese 
encephalitis virus and Murray Valley encephalitis virus. Damages to the meninges 
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contributing to meningitis, the brain parenchyma causing encephalitis and the spinal 
cords leading to myelitis, have been observed from pathological findings.  Many 
immunocompromised patients had succumbed to neurological manifestations caused by 
WNV infections (George et al., 1984). In North America, patients were reported to be 
suffering from acute flaccid paralysis resembling poliomyelitis (Sejvar et al., 2003). 
There is also a higher incidence of severe diseases, especially in the elderly people 
possibly due to slower and weaker immune response (OLeary et al., 2002; Zeller and 
Schuffenecker, 2004).  
West Nile virus is one of the most widely distributed arthropod-borne virus 
extending from Africa, the Middle East, Europe, central Asia and Oceania (Brinton, 
2002). The first epidemic affecting humans was reported in Israel in 1951. Subsequently, 
more epidemics were recorded in Israel (1957 and 1962) and France (1962), with the 
appearance of neurological diseases (Hayes, 1989). In the past ten years, there has been 
an increase in the frequency and severity of WNV outbreaks in the Mediterranean Basin 
and southern Europe. During the 1996 Romanian outbreak several patients developed 
symptoms with central nervous system involvement (Zeller and Schuffenecker, 2004). In 
addition, WNV has been the causative agent of brief epizootics in Russia, Algeria, 
Madagascar, France, Senegal and South Africa.  
In 1999, an unexpected WNV outbreak occurred in New York City in the United 
States of America, involving human and animals, mainly horses and birds. The isolated 
virus was found to be closely related to the Israel strain Isr98 which had been circulating 
in Israel since 1997 (Petersen and Roehrig, 2001). There were about 60 cases of human 
WNV infection reported in 1999 and the total number of WNV disease had since jumped 
drastically to 23,889 at the end of 2006 with forty percent being reported as 
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neuroinvasive disease (Hayes and Gubler, 2006; CDC, 2006). This outbreak in the US 
had demonstrated the dramatic movement of this virus outside of its normal geographic 
distribution and poses a great threat to the public health (Jia et al., 1999; Lanciotti et al., 
1999).  
The mode of introduction of WNV into North America is unclear. It was 
speculated that the movement of WNV to the Western Hemisphere was caused by 
migratory birds that acted as introductory hosts, perhaps by infecting ornithophilic 
mosquitoes. Once introduced, the virus could have found competent vectors, susceptible 
amplifying hosts and efficient mechanisms for survival during the winters (Rappole et al., 
2000).   
 
1.6 DIAGNOSIS OF WNV INFECTION AND DEVELOPMENT OF ANTIVIRAL 
STRATEGY AGAINST WNV 
West Nile virus infections can be diagnosed through a combination of clinical 
presentations and positive results of laboratory findings. The most frequently used 
method in the laboratory is serological-based ELISA which detects the presence of IgM 
in patients serum. Identification of IgM in the cerebrospinal fluid is necessary to 
establish WNV-associated neurological infections as IgM do not cross the blood brain 
barrier and their presence in the brain is indicative of antigenic exposure. Polymerase 
chain reaction (PCR) has been employed to screen for the presence of WNV in donated 
blood and products (Thereses, 2002; Tyler, 2004).    
   Currently, there is no specific therapy or vaccines approved for use in humans 
to prevent WNV-infection; hence patients suffering from WNV-associated diseases are 
given supportive treatments (Tyler, 2004; Bai et al., 2005). The antiviral drug Ribavirin 
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and interferon alpha-2a and -2b were found to inhibit WNV replications in vitro but they 
were not effective in treating infected patients. Similarly, passive immunization of anti-
WNV antibodies to infected individual was of limited success (Tyler, 2004). Few 
vaccines are available for enhancing immunity against West Nile virus infections in 
animals. They include formalin-inactivated WNV, WNV DNA vaccines and chimeric 
live WNV vaccines which incorporate WNV genes into other flavivirues backbones 
(Chang et al., 2004; Hall and Khromykh, 2004; Huang et al., 2005). However, there are 
still no vaccines approved for human use. An alternative strategy to combat WNV 
infections is through the disruption of WNV protein translation and/ or RNA replication 
in the infected cells. 
  
1.9 RNA INTERFERENCE 
 
RNA interference (RNAi) is a biological process whereby RNA molecules 
regulate the expression of genes. This was first observed in plants in the early 1990s 
where the introduction of genes into the plants resulted in homology-dependent silencing 
of the plants endogenous genes (Napoli et al., 1990; van der Krol et al., 1990). The 
introduction of RNAs using RNA viral vectors in the absence of DNA template caused 
specific endogenous gene silencing in plants support the notion of a RNA-mediated 
process (Wassenegger, et al., 1994). In addition, many groups have discovered that plants 
responded to RNA viruses by targeting viral RNAs for destruction. (Ruiz et al., 1998). 
The puzzling phenomenon became clear when Fire and colleagues (1998) demonstrated 
gene silencing operating at post-transcriptional level in the nematode worm 
Caenorhadbitis elegans when they injected double-stranded RNAs (dsRNAs) into the 
worm. The plant systems also illustrated the depletion of mRNA sequences without any 
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apparent effect on the rate of transcription when exposed to dsRNA (de Carvalho et al., 
1992). The long dsRNAs were later found to be cleaved into 21-23 nucleotide (nt) 
fragments in a ATP-dependent hydrolysis and used to guide mRNA cleavage (Zamore et 
al., 2000). The species was given the name small interfering RNA [(siRNA) (Elbashir et 
al., 2001)].  
 The introduction of dsRNAs and transgenes into experimental models producing 
silencing effects prompted a search for short RNAs encoded by the host genomes. A class 
of non-coding small RNA dubbed as microRNA (miRNA) was found to be present in 
both members of the plant and animal kingdoms (Lim et al., 2003). They are single 
stranded and 19-25 nt in length. Some of these miRNAs enters the RNAi pathway and 
regulate the expression of mRNAs (He and Hannon, 2004). 
RNA interference is a mechanism of genetic regulation in multicellular 
organisms. It exerts silencing effects on transposable elements or jumping genes and 
repetitive genes, hence guarding the integrity of the host genome (Novina and Sharp, 
2004). It is also a form of immune defence that protects eukaryotes against viruses and in 
some respect this is conceptually similar to classical humoral immunity (Ding et al., 
2004; Ronen et al., 2004). However, RNA silencing is distinct from humoral immunity in 
that it only targets nucleic acids and has a specificity mechanism based on nucleic acid 
base pairing rather than on interactions with protein antibodies. In addition, RNAi is 
believed to function as a developmental regulator of cellular gene expression where it 
limits the amount of gene products produced in the certain tissues either by translational 
repression or mRNA degradation. It is also involved in heterochromatin formation (He 




1.8 MECHANISM AND PROTEINS INVOLVED IN RNA INTERFERENCE 
 
It has been established that RNAi and virus-induced gene silencing share 
mechanistic similarities. The primary mechanisms underlying dsRNA-induced gene 
silencing was elucidated from genetic studies in C.elegans, plants and from biochemical 
studies from Drosophila extracts while the discovery of miRNA was made through a 
genetic screen in C.elegans (Hannon, 2002; Bartel, 2004). The convergence of 
observations from these diverse experimental systems led to the emergence of a model 
for RNA interference and related silencing phenomenon (Figure 1.4).  
Primary miRNA (pri-miRNA) of several hundreds nt in length are first 
transcribed from the host genome and further processed by the protein, Drosha, into 
smaller 70 nt long pre-miRNAs with stem-loop structures in the nucleus. Drosha contains 
variable long N-terminal regions, two RNase III domains and a double-stranded RNA 
binding domain (dsRBD). The latter domain composed of 70 amino acids is characterised 
by a αβββα fold with the α-helices sitting against the β-sheets. The presence of an 
additional helix at the C-terminal forces the RNA to interact with the first helix of the 
dsRBD and cause the binding of hairpin structure of the dsRNA to the RNase III domain. 
Hence, this domain is responsible for recognising and binding to the stem-loop structures 
in pri-miRNA. The RNase III domain then generates pre-miRNAs with 3 2 nt 
overhangs. The pre-miRNA is then transported out of the nucleus by exportin-5 for 












Figure 1.4 Overview of the RNAi mechanism (Leung and Whittaker, 2005)  
 
In the cytoplasm, both the long dsRNA and pre-miRNA are cleaved by the 
ribonuclease III enzyme, Dicer protein, into approximately 21-nt fragments (Hammond, 
2005). The Dicer protein comprises several domains namely, N-terminal RNA helicase 
domain, Piwi/Argonaute/Zwillie (PAZ) domain, two RNase III domains and dsRBD 
(Figure 1.5). It has been postulated that the two RNase III domains dimerize to form a 
single processing centre and each catalytic site cleaves one strand of the double-stranded 
substrates giving rise to products with 3 2 nt overhang. The PAZ domain is made up of 
110 amino acids and it is also found in the Argonaute (Ago) proteins. The most 
prominent property of the PAZ domain is the ability to discriminate 3 2 nt. Both PAZ 
and RNase III domains are required for Dicer activity. They act as a ruler in a way where 
the distance between the PAZ domain and the terminal end of the long dsRNA or pre-
miRNA bound to the RNase III endonucleolytic site is 21 nt. Hence, during the process, 
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Figure 1.5 Schematic diagram of Dicer with multiple domains (Hammond 2005) 
 
The double-stranded siRNA or miRNA then dissociated in the RNA-inducing 
silencing complex (RISC) loading complex and give rise to the guide strand and the 
passenger strand. The guide strand, which has a thermodynamically less stable 5 end, is 
then incorporated into the Ago effector complexes, RISC while the passenger strand is 
discarded (Tomari et al., 2004). RISC contains one or more proteins of the Argonaute 
family (Hammond et al., 2001). The detail mechanism of this transfer is unknown.  
One of the Ago protein subset possess nuclease activity and mediates cleavage of 
the target mRNA. There are 4 domains in the Ago protein namely the N-terminus, middle 
Lac-Z-like domain, PAZ domain and the PIWI domain. The latter domain is 
characterized as the Slicer and is folded in a way similar to RNase H (Song et al., 
2004). It contains a triad of amino acids DDH which is involved in the catalysis of RNA 
(Liu et al., 2005; Rivas et al., 2005). The 5terminal nt of the guide binds to the PIWI 
domain and the 3 end interact with the PAZ domain of Ago [(Lingel et al., 2004) (Figure 
1.6)]. The complex then binds to target mRNA by complementary base pairing rule. 
Those that are able to form tight guide/target helices by extensive base pairing will result 
in cutting of the target RNA in an ATP-independent reaction. This takes place between 
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residues paired to nt 10 and 11 of the siRNA or miRNA (Tomari et al., 2004). The 
fragmented target RNA is then released from the complex with the help of RNA helicase 
and ATP. Those guide/target duplexes with less complementary base pairing will result 







Figure 1.6 Model for Slicer activity (Hammond 2005). (A) The 5 terminal and 3 
terminal of guide strand interact with PIWI and PAZ domains respectively. (B) The 
complex binds to target mRNA by complementary base pairing. (C) Cleavage of target 
mRNA.  
 
1.9 GENERATION OF siRNA 
There are several methods to generating siRNAs: chemical synthesis, in vitro 
transcription, digestion of long dsRNA by an RNase III family enzyme, expression in 
cells from a siRNA expression plasmid or viral vector, and expression in cells from a 
PCR-derived siRNA expression cassette.  
Chemically synthesized siRNA was first introduced into mammalian cells by 
Elbashir and colleagues (2001). They showed that the synthetic siRNAs were functional 
in vivo by co-transfecting Drosophila S2 cells with luciferase siRNA and a luciferase 




obtained with long dsRNA (Hammond et al., 2000). More importantly, they showed that 
siRNA transfection resulted in the sequence-specific silencing of luciferase expression in 
several mammalian cell lines without activating non-specific effects. In addition, 
synthetic siRNAs duplexes can be delivered to targeted sites with the use of carriers such 
as specific immunoliposomes which bind to specific cell receptors (Zhang et al., 2004). 
However, these siRNAs and carriers are expensive to produce and it is tedious to produce 
novel monoclonal antibodies. Moreover, RNAs are not easily transfected in all cell types, 
especially the primary cells. Hence, only limited siRNAs are introduced into the cells. 
The effects exerted are also short termed as there is absence of RNA-dependent RNA 
polymerase to amplify siRNAs in the mammalian cells and the dilution of the duplexes in 
the growing cell culture and/or degradation of transfected siRNAs (Cullen, 2004; Leung 
and Whittaker, 2005). Another disadvantage of using long synthetic RNA dulplexes is the 
potential of activating RNA-binding protein kinase (PKR) and RNase L resulting in the 
inhibition of all protein systhesis as well as activation of interferon response (Bass, 2001; 
Robbins and Rossi, 2005).   
There has been no report showing the presence of siRNA replication in mammals 
when compared to the fungi (Cogoni and Macino, 1999), plants (Dalmay et al., 2000) and 
worms (Sijen, et al., 2001). Hence, RNAi by transfection of chemically-synthesized 
siRNAs is transient in nature in Drosophila and mammals. To overcome some of the 
shortcomings of the transfection of chemically-synthesized siRNA into cells, several 
groups have developed vector-mediated mechanisms (both DNA vector and viral vectors) 
to express substrates that can be converted into siRNA in vivo (Brummelkamp et al., 
2002; Paul et al., 2002; Tuschl, 2002). Currently, vector systems that direct synthesis of 
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siRNAs in mammalian cells (Agami et al., 2002; Taira and Miyagishi, 2002) are the 
methods of choice.  
Vector-based expression systems using RNA polymerase (pol III) promoters that 
produce short RNA species and do not trigger significant interferon responses have been 
developed (Brummelkamp et al., 2002). Two pol III promoters have been used 
predominately  the U6 promoter and the H1 promoter. Both of these promoters are 
members of the type III class of pol III promoters. Although the U6 and H1 promoters 
contain the same set of cis-acting elements (octamer motif, Staf-binding site, proximal 
sequence element (PSE) and TATA motif), the H1 promoter has a more compact 
organization (Myslinski et al., 2001).  
Two approaches have been used for the expression of siRNA species by 
constructs that are driven by RNA pol III (Figure 1.7). In the first design, the sense and 
antisense strands of the siRNA are expressed from two different U6 promoters either in 
tandem or in two different vectors. In vivo, these strands come together to form a 19-nt 
duplex with 4-nt overhangs from the pol III termination signal. Alternatively, short 
hairpin RNAs (shRNAs) are expressed by H1 promoters and processed by Dicer into 
siRNAs. From various studies, shRNA expression vectors showed a greater suppression 
activity than the tandem-type of expression systems at low concentration (Miyagishi and 



















Figure 1.7 Vector based expression of siRNA (Leung and Whittaker, 2005)  
 
Originally identified for its ability to cleave long dsRNA, in vitro and in vivo data 
have shown that Dicer can process hairpin RNA structures. Dicer is required for the 
processing of pre-let7 RNA, which is a structured approximately 70-nt hairpin, into the 
mature 22-nt active species miRNA (Reinhart et al., 2000). Brummelkamp and 
colleagues (2002) designed an H1 RNA-pol-III-based shRNA expression vector (known 
as pSuper) to produce hairpin RNA with a 19-nt stem and a short loop. It was later shown 
that 25-29 base pairs in length stems give rise to better RNA processing and siRNA 
expression than shorter stems do. Short hairpin RNAs with stems longer than 29 base 
pairs as well as the presence of immunostimulatory RNA motif tend to induce interferon 
response in the host and should be avoided (Judge et al., 2005; Hormung et al., 2005). 
The 5 of the guide strand should be poorly base-paired to promote loading to the 
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Argonaunt effector complex (Schwarz et al., 2003). In addition, five thymidine residues 
should be incorporated into the design of shRNAs to allow transcriptional termination by 
the RNA polymerase. This also allows the shRNAs to acquire a 2 nt 3 overhang, a 
feature required by the Dicer (Yi et al., 2003).  
Although, both viral and DNA-based vectors can be used for long term expression 
of shRNAs in the cells, DNA-based vectors are still preferred over the viral counterparts. 
Viral vectors are presented with problems similar to those of gene therapy including the 
safety concerns and heightened regulatory analysis (Aigner, 2006). In addition, when 
used as a form of antiviral strategy, genetic recombination may occur between the vector 
virus and the targeted pathogenic virus. The advantages of using the DNA-vector system 
include higher intrinsic stability of transiently transfected DNA which in turn allow 
amplification of shRNAs. On top of that, this system can be integrated into the host 
genome or exist as episomal form for stable expression of shRNAs (Uprichard, 2005). 
 
1.10 INTERFERING WITH DISEASES 
Introduction of siRNA into mammalian cells has now been used to silence a wide 
range of genes in a variety of cell types. An ever-increasing number of reports have 
probed potential therapeutic uses against cancer, autoimmune diseases, 
neurodegenerative diseases and viral infections.  
The potential impact of RNAi on viral infections had been demonstrated both in 
vitro and in vivo. siRNAs had been shown to be effective against both DNA and RNA 
viruses with diverse replication strategies. It can act as a prophylactic agent preventing 
viral infections or lower viral loads through inhibition of viral protein production and 
transcription of viral genomes (Tan and Yin, 2004). Several groups have targeted Human 
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Immunodeficiency Virus (HIV) regulatory genes, leading to decreased virus production 
(Lee et al., 2002; and Coburn and Cullen, 2002). Other viruses including Poliovirus 
(Gitlin et al., 2002), Hepatitis C (Yokota, 2003), Human Papilloma virus (Yoshinouchi et 
al., 2003), Influenza (Ge et al., 2003) and Severe Acute Respiratory Syndrome [(SARS) 
(Wu et al., 2005)] were also successfully targeted by siRNAs, providing a basis for 
further developments of anti-viral siRNAs. In addition, a few studies also made use of 
RNAi technology to disrupt WNV replication by targeting the UTRs of the viral genome 
(Deas et al., 2005), envelope (Bai et al., 2005; Kumar et al., 2006), capsid and NS5 
(McCown et al., 2003; Geiss et al., 2005) genes in both in vitro and in vivo systems. In 
all cases, however, the emergence of siRNA resistance is a major concern that will need 




The few studies that were conducted to target WNV have some pitfalls in the 
systems used. These included the production of replication competent virus with the use 
of a viral vector system and the absence of long term siRNA expression with the use of 
chemically synthesized siRNA or plasmid systems that may be lost after cell divisions. 
Therefore, this study attempted to overcome some of these problems by using plasmid-
based expression system which allowed the option of creating stable cell lines expressing 
shRNAs under the control of a RNA polymerase III promoter. The sensitivity and 
susceptibility of the WNV to shRNAs designed against various sites in the virus genome 
were also investigated. This study also examined the morphological changes induced by 
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siRNA silencing. The technology of RNAi can provide a rapid technique for studying 
















   Materials & Methods 
 23
2.0 MATERIAL AND METHODS 
2.1 CULTIVATION AND PROPAGATION OF CELL LINE  
Vero cells, a gift from Emeritus Professor E. G. Westaway, Australia, were used 
throughout this study.  The passage level of the cell line used was between 25 to 90. The 
cells were maintained in M199 (Appendix 1a) supplemented with 10 % foetal calf serum 
(FCS) in sterile tissue culture flasks (Nunc, Denmark). During passaging, the cell 
monolayer was washed with phosphate buffered saline [(PBS) Appendix 1b] and then 
exposed to trpysin-versene (Appendix 1d). The flask was incubated for 2 min at 37 oC to 
detach the cell monolayer from the flask. When rounding of cells was observed, the flask 
was tapped gently to detach the cell monolayer. Five ml of M199 with 10 % FCS 
(Appendix 1a) were added immediately to reduce the enzymatic effect of trypsin-versene 
solution. The suspended cells were then reseeded into new sterile flasks with new 
medium added and incubated in 37 oC until the cell monolayer was confluent. 
For the cultivation of Vero cells in 24-well tissue culture plates (Nunc, Denmark), 
cell monolayers of 90 % confluency grown in 75 cm2 flasks were used. The cell 
suspension was made up to a final volume of 240 ml using M199 with 10 % FCS 
(Appendix 1a). One and a half ml and 2 ml of the suspension was added to each well of 
the 24-well plates to achieve 70 % and 90 % confluency (within 24 h of incubation), 
respectively.  The plates were then incubated at 37 oC in the 5 % CO2 incubator overnight 
before use. To attain 70 % to 90 % confluency after 24 h in 12-well tissue culture trays, 
3.5 ml and 4.5 ml of suspended cells were transferred to each well, respectively.  
Cells were grown on pretreated glass coverslips of diameter 13 mm (Chance 
Propper, UK) for indirect immunofluorescence microscopy. The coverslips were washed 
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with 95 % ethanol for 30 min and boiled in deionized water for 10 min. They were then 
left to air dry before sterilizing at 160 oC for 2 h. 
Each coverslip was aseptically placed in each well of the 24-well tissue culture 
plate. A confluent monolayer in 75 cm2 flask was used to propagate the cells and was 
treated in a similar fashion, as above. The amount of suspension added to each well 
depended on the desired confluency after 24 h.  
 
2.2 INFECTION OF CELLS 
2.2.1 Virus Strain 
West Nile virus (WNV), strain Sarafend was a gift from Professor Westaway 
(Australia). It is a lineage two virus of uncertain origin and it has a high level of 
laboratory passage (Scherret et al., 2002).  The virus was propagated in Vero cells 
throughout the study. 
 
2.2.2 Propagation of WNV  
West Nile Virus was grown in Vero cells. A confluent flask (75 cm2) of Vero 
cells was washed once with PBS (Appendix 1b). One ml of virus was added onto the 
cells and incubated at 37 oC for an h with rocking at every 15 min interval to ensure an 
even distribution of virus over the monolayer. Twelve ml of M199 (Appendix 1c) 
supplemented with 2 % FCS was added into the flask and incubated at 37 oC for 1-2 days. 
Virus was harvested by centrifuging down the cells and aliquoting 500 µl of the 
supernatant into 1 ml sterile vials (Nunc, Denmark). The virus was snap frozen in cold 
absolute ethanol before storing at 80 oC. 
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2.2.3 Plaque Assay 
Plaque assays were carried out to quantify viruses. Ten-fold serial dilutions of the 
WNV virus sample were prepared in virus diluent (Appendix 2a). Confluent Vero cell 
monolayer was washed with PBS (Appendix 1b). One hundred µl of the appropriate 
dilutions were added to wells of a 24-well plate containing one-day-old confluent Vero 
cell monolayer.  Mock-infected cells using virus diluent and undiluted virus obtained 
from section 2.2.2 were used as negative and positive controls, respectively. The virus 
was allowed to absorb to the cells at 37 oC for an h with gentle rocking at 15 min 
intervals. After an h, excess inoculate were removed and the monolayer was washed with 
PBS (Appendix 1b). One and a half ml of 1% w/v carboxymethylcellulose (CMC) in 
M199 media (Appendix 2b) was then layered onto the infected cell monolayer. Plates 
were further incubated at 37 oC in 5 % CO2 incubator for 3 days. Visualization of plaques 
was achieved by addition of approximately 200 µl of 1 % crystal violet solution 
(Appendix 2c). The plate was agitated for one and a half h before thorough rinsing with 
water and the plate was dried before counting the plaques. 
 
2.2.4 Infection of Cells Grown in 12-Well and 24-Well Tissue Culture Plates 
Cells growing in 12-well or 24-well tissue culture plates or on coverslips in 24-
well plates (Section 2.1.) were then infected with WNV virus at the multiplicity of 
infection (M.O.I.) of 10. 
The monolayers in the wells were washed with 1 ml of PBS (Appendix 1b). After 
PBS has been discarded, 150 µl and 100µl of virus were added to each well of cells in a 
12-well and 24-well plate, respectively. For mock-infected cells, 100 µl or 200 µl of virus 
diluent (Appendix 2a) was added to the well. The plates were then incubated in a 37 oC 
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incubator for 1 h with rocking every 15 min. After incubation, the cells were washed with 
PBS (Appendix 1b) and 1.5 ml of medium M199 with 2 % FCS (Appendix 1c) was 
added to each well. The cells were then incubated until the appropriate time post 
infection. 
 
2.2.5 Infection of Cells Grown in T75 Flasks 
Confluent one-day-old monolayers Vero cells grown in T75 flasks (Section 2.1) 
were then infected with WNV at the M.O.I. of 10.  The cells in the flasks were washed 
with PBS (Appendix 1b) and 1ml of virus was added to each flask. For mock-infected 
cells, 1ml of virus diluent was added to each flask. The flasks were then incubated in a 37 
oC incubator for 1 h with rocking every 15 min. After incubation, excess inocula were 
removed and the cells were washed with PBS (Appendix 1b). Ten ml of medium M199 
with 2 % FCS (Appendix 1c) was added to each flask. The cells were then incubated until 
the appropriate time post infection. 
 
2.3 MOLECULAR CLONING 
2.3.1 Cloning of Short Hairpin RNA (shRNA) Inserts into pSilencer Vectors  
The open reading frame WNV (Sarafend) (GenBank; AY688948) was used to 
identify various target sites against the virus genome using the software program siRNA 
Target Finder provided by Ambion, USA 
(http://www.ambion.com/techlib/misc/siRNA_finder.html). The algorithm selects siRNA 
targets by searching for AA dinulcleotides in the mRNA sequence and its downstream 
nucleotides with GC content ranging from 30-50 %. In addition, the selected siRNA 
targets should have a higher G/C content at its 3 end and lower G/C content at its 5 end 
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for the antisense strand. Four target sites were selected and the sequences were used to 
design oligonucleotides. Scrambled sequences for each of the target site were also 
generated using software program InvivoGen's siRNA Wizard hosted by Invitrogen, 
USA at http://www.sirnawizard.com/scrambled.php (Table 2.1). No homology with 
monkey or human genome was found for these scrambled sequences.  
 




Name of target construct/ 
Sequence of bottom strand 
oligonucleotide  (5-3)  
Name of scrambled vector- 
control construct/ Sequence of 









































































Target sequence are indicated in bold 
 
The ligation process was performed using the pSilencerTM siRNA expression kits 
(Ambion, USA), as recommended by the manufacturer. Each pair of oligonucleotides 
was allowed to anneal to its corresponding complementary strand before ligating to either 
the linearized vector pSilencerTM 3.0-H1 or its improved version of the same vector, 
pSilencerTM 3.1-H1 neo, via the BamH I and Hind III restriction sites at the 5 and 3 end, 
respectively.  Both vectors contain a human H1 RNA polymerase promoter site that 
allows the expression of shRNA, which can be further, cleaved by Dicer to give siRNA. 
pSilencerTM 3.1-H1 neo in additionally contains G418 antibiotic selection marker to 
allow selection of positively transfected cells. 
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2.3.2 Transformation of Competent Escherichia Coli Cells  
Transformation was carried out using One Shot® TOP 10 Chemically Competent 
E.coli cells (Invitrogen, USA) according to the manufacturers protocol. Two µl of the 
cloning reaction (Section 2.3.1) was added to a vial of One Shot® TOP 10 Chemically 
Competent E.coli cells and mixed by tapping gently before incubating on ice for 30 min. 
The cells were then subjected to heat shock at 42 oC for 30 sec and immediately 
transferred back into ice for another 2 min. Two hundred and fifty µl of SOC medium 
(Invitrogen, USA) pre-warmed to room temperature was then added to the vial and the 
cells were incubated at 37 oC for 1 h with shaking at 200 rpm for recovery from the heat 
shock. Following the recovery, 100-200 µl of the cells was then plated onto pre-warmed 
LB agar plates (Appendix 3a) each containing 100 µg/ml ampicillin and incubated 
overnight at 37 oC. 
 
2.3.3 Isolation and Purification of Plasmid DNA from Escherichia Coli  
A single colony of each E.coli transformant obtained from section 2.3.2 was 
inoculated into 2 ml of fresh LB broth (Appendix 3b) containing 100 µg/ml ampillicin 
and incubated overnight at 37 oC with shaking at 200 rpm. The cells were then harvested 
by centrifugation (Eppendorf, Germany) at 14,000 rpm for 5 min. The extractions of 
recombinant plasmids were done using QIAprep Spin Miniprep Kit (QIAGEN, USA), 
according to the manufacturers protocol. Thirty µl of autoclaved Type 1 reagent grade 
water H2O (NANOpure II, Barnatead, USA) was used to elute the plasmids from the 
column instead of the suggested Elution Buffer. Extracted plasmids were then stored at 
20 oC until required. 
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2.3.4 DNA Sequencing  
DNA sequencing was carried out to verify that the inserts in the vector constructs 
were in the correct orientation. DNA sequencing was performed using the forward primer 
as describe in Table 2.2 and ABI PRISM BigDyeTM Terminator Cycle Sequencing Ready 
Reaction Kit (Applied Biosystem, USA). The composition of the sequencing reaction 
was 6 µl of DNA, 5 µl of sequencing reaction kit and 1 µl of primer. Sequencing profiles 
and the purification of the extended product was performed according to the 
manufacturers protocol. Ethanol precipitation was carried out to extract the extension 
product. The precipitated sample was then stored in 20 oC until they were sent for 
electrophoresis at the National University Medical Institute (NUMI) sequencing 
laboratory or Life Science Laboratory Four at National University of Singapore. Both the 
sequencing chromatogram and the sequence date file were subsequently obtained from 
NUMI. The sequences obtained were then checked for correct oligonucleotide insertion. 
 
Table 2.2 Primer used for sequencing vector constructs 
Vector Primer Sequence 5  3 
pSilencer 3.0-H1 or 
pSilencer 3.1-H1 neo 
GTTTTCCCAGTCACGAC 
 
2.3.5 Scaling Up of Vector Constructs  
Once the transformants from section 2.3.3 were confirmed to contain the right 
vector constructs, the QIAGEN Endofree Plasmid Maxi Kit (QIAGEN, USA) was used 
to scale up the quantities of the plasmids from the transformants. This was performed 
according to the manufacturers protocol. The E.coli transformant obtained in section 
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2.3.3 was inoculated into 2 ml of fresh LB broth (Appendix 3b), containing 100 µg/ml 
ampicillin and incubated at 37 oC for 8 h with shaking at 200 rpm to obtain a starter 
culture. This starter culture was then transferred to 250 ml of fresh LB broth (Appendix 
3b), containing 100 µg/ml ampicillin and incubated at 37 oC overnight with shaking at 
200 rpm. The cells were then harvested by centrifugation (Joaun centrifuge) at 6000g for 
15 min at 4 oC and the plasmids extracted. Extracted plasmids were dissolved in 300 µl of 
autoclaved Type 1 reagent grade water H2O (NANOpure II, Barnatead, USA) and were 
then stored at 20 oC. The DNA was used for transfection in section 2.4. 
 
2.3.6 Nucleic Acid Quantification 
Extracted DNA form section 2.3.5 was quantified by diluting 1 µl of DNA in 99 
µl of autoclaved ddH2O. The sample was then read in a spectrophotometer (Shimadzu-
UV 1601, Japan) at wavelength of 260 nm and 280 nm. Pure DNA preparation will have 
a ratio of OD260/280 equal to 1.8. An absorbance of 1 OD unit at 260 nm is equivalent to 
50 µg/ml of dsDNA.  
 
2.4 TRANSFECTION  
2.4.1 Lipofectamine PlusTM Transfection  
Cell monolayers with a confluency of about 50  70 % were used for transfection. 
Transfections were performed by using Lipofectamine Plus reagents (Invitrogen, USA) 
according to the manufacturers protocol.  Two µg of the plasmid was complexed with 4 
µl of Plus reagent in 25 µl of OPTI-MEM medium (Gibco, USA) for 15 min at room 
temperature. The mixture was then added to 25 µl of OPTI-MEM containing 2 µl of 
Lipofectamine. After incubation for another 15 min, the DNA-liposome complexes were 
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added to the Vero cells that were grown overnight in 24-well tissue culture plates. After 
incubation for 3 h at 37 °C, 1 ml of complete growth medium (Appendix 1a) was added. 
For negative control, autoclaved Type 1 reagent grade water H2O (NANOpure II, 
Barnatead, USA) was added instead of DNA. The amount of reagents used were doubled 
for transfecting cells grown in 12-well tissue culture plates. 
 
2.4.2 Selection of Stably-Transfected Vero Cells 
Prior to selection of stably-transfected cells, the minimum concentration of 
antibiotic G418 (Sigma, USA) to kill the non transfected cells was determined. Antibiotic 
G418 that acts as the selection agent was added at a concentration of 400 µg / ml to the 
wells 48 h after transfection to select for positively-transfected cells. Old culture medium 
was replaced by fresh M199 with 10 % FCS (Appendix 1a) containing 400 µg/ml of 
G418 every 48  72 h. Passaging was the same as described in section 2.1.  
 
 
2.5 Evaluation of Transfection Induced Cytotoxicity 
The release of lactate dehydrogenase (LDH) was detected using CytoTox 96 
(Promega, USA) in accordance with manufacturers protocol. Vero cells were seeded into 
24-well plate as described in section 2.1 and the supernatants were collected from 
transiently-transfected cells after 24 h. Similarly, the stably-transfected cells were seeded 
overnight before the supernatants were collected.  For each sample, 50 µl per well was 
transferred to 96-well plates (Nunc, Denmark). Freshly prepared substrate provided by 
the kit was added to each well and incubated in the dark at room temperature for 30 min. 
The reactions were stopped and the activity of LDH was determined. The concentration 
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of metabolized substrate, which is a function of the LDH activity, was determined using 
an ELISA plate reader at an absorbance of 490 nm.  
 
2.6 GENOMICS EXPRESSION STUDIES 
2.6.1 Total RNA Isolation from Cell Culture 
Total RNA was extracted from transfected and WNV-infected Vero cells (Section 
2.2.4) at 12- and 24 h p. i. As described in the protocol of Qiagen Rneasy Mini Kit 
(USA), the cells were lysed and mRNA was collected with the inclusion of an additional 
DNase digestion step to remove contaminating genomic DNA. The samples were 
dissolved in DEPC water and stored at 80 oC.  
 
2.6.2 Reverse Transcription Polymerase Chain Reaction (PCR) 
Complementary DNA (cDNA) was synthesized from the viral RNA using the 
SUPERSCRIPT II RNase H- Reverse Transcriptase (GIBCOBRL® Life Technologies, 
New Zealand). The synthesis was conducted according to the manufacturers protocol. 
WNV gene-specific primer (Table 2.3) that corresponds to the WNV envelope (E) gene 
sequence was used in the reverse transcription PCR to generate its cDNA. β-actin cDNA 
was also generated in the same reaction using a corresponding gene-specific primer 
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Table 2.3 Primers used for reverse transcription to generate cDNA 
Target  Primer Sequence (5-3) 
WNV E RNA WNV (E) rev trans AGCATGGACGTTGACCGAAAGG 
Actin RNA ACTIN rev trans CTAGAAGCATTTGCGGTG 
 
 
2.6.3 Real-Time Polymerase Chain Reaction (RT-PCR) 
Real time PCR (RT-PCR) was carried out to quantify the copy numbers of the E 
protein gene and β-actin gene. The primers used for RT-PCR are listed in Table 2.4 
 
Table 2.4 List of primers in real-time PCR 
Target Primer Sequence (5-3) 
WNV cDNA WNV RT-PCR (FOR) TCCCTGAACGACCTTACACC 
WNV cDNA WNV RT-PCR (REV) ACTAAACGGGGGTTCGAGTT 
Actin cDNA ACTIN RT-PCR (FOR) CGGGACCTGACTGACTACCT 
Actin cDNA ACTIN RT-PCR (REV) TGATCCACATCTGCTGGAAG 
 
A 25 µl reaction mixture contained 2 µl of cDNA, 12.5 µl of Platinum SYBR 
Green (Invitrogen, USA) and 1 µl each of the forward and reverse primers. The negative 
control contained all SYBR green reagents except DNA. Reactions were cycled at 50°C 
for 2 min and then 95 °C for 2 min, followed by 45 cycles of 95 °C for 15 sec, 60 °C for 
30 sec and 72 °C for 30 sec, followed by a melting curve analysis.  
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2.7 INDIRECT IMMUNOFLUORESCENCE MICROSCOPY 
For immunofluorescence microscopy, the cells were cultivated on coverslips as 
described in section 2.1. For transient transfection, cells were seeded to give 70 % 
confluency. West Nile Virus infection as described in section 2.2.4 was carried out 24 h 
post transfection. Stably-transfected cells were seeded overnight to give 90 % confluency 
before being used for infection. Mock-infected cells using virus diluent (Appendix 2a) 
were used as negative control.  
At 12- and 24 h post infection (p. i.), the monolayers were washed three times 
with PBS (Appendix 1b) to remove media. This was then followed by fixation in cold 
methanol (Merck, Germany) at 10 oC for 10 min. The cells were then washed with PBS 
(Appendix 1b) for 5 min, with shaking. This was repeated for another two times. 
Blocking step was then carried out by incubating the cells in 1 % bovine serum albumin-
PBS [(BSA-PBS) (Appendix 4a)] for 15 min.  
The primary antisera used are listed in Table 2.5. They were diluted to an 
appropriate concentration using PBS (Appendix 1b). Fifty µl of the antiserum were 
spotted on a piece of parafilm (American National Can, Canada). The coverslips were 
then inverted with the cells facing the antiserum and incubated in a humidified 
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Table 2.5 Working dilutions for antibodies used in immunofluorescence microscopy 
Type of antibody Name Dilution Source 
Primary, polyclonal Rabbit a anti-WNV 
Capsid  





Primary, polyclonal Rabbit a anti-WNV 
NS2B 





Primary, polyclonal Rabbit a anti-WNV 
NS4B  





Primary, polyclonal Rabbit a anti-WNV 
NS5 














After the incubation period, excess antibodies were washed off thrice with 1 % 
BSA-PBS (Appendix 4a), each for 5 min at room temperature with shaking. The 
coverslip of washed cells were inverted over 50 µl of the secondary antibodies spotted on 
a piece of parafilm. The cells were then placed in the 37 oC incubator with humidified 
condition for 1 h. Upon the completion of incubation period, the coverslips were washed 
in 1 % BSA-PBS (Appendix 4a) for 5 min, with shaking. The washing step was repeated 
for another two times.  
The coverslips were then mounted on glass slides using about 10 µl of DABCO 
mountant (Appendix 4b). Excess mountant were removed by blotting. The samples were 
viewed under 1X-81 microscope (Olympus, Japan) at an excitation wavelength of 
480 nm for FITC using oil immersion objectives under 100X magnification with the 
Metamorph imaging software program.   
 
2.8 PROTEIN ANALYSIS 
2.8.1 Extraction of Proteins 
Vero cells were grown in 12-well tissue culture plates as described in section 2.1. 
Cells were seeded overnight to give 70 % confluency before proceeding with transient 
transfection. West Nile Virus infection as described in section 2.2.4 was carried out 24 h 
post transfection. Stably-transfected cells were seeded overnight to give 90 % confluency 
before using for infection. Mock-infected cells using virus diluent were used as negative 
control.  
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At 12- and 24 h p. i., the cell monolayer was washed thrice with PBS (Appendix 
1b). The cells were lysed using 150 µl of 2 % SDS for 10 min on ice. The supernatant 
was then pipette into an eppendoff tube containing 25 µl protein loading buffer, glycerol-
bromophenol blue dye and dithioerytritol mixture (Appendix 5a). The sample was then 
boiled for 5 min and stored at 20 oC until required. 
 
2.8.2 SDS-PAGE 
The electrophoresis technique for protein separation was the Laemmli 
discontinuous gel system (Laemmli, 1970). The electrophoresis apparatus used was from 
Amersham Biosciences, UK. 
A 12 % separation gel (Appendix 5b) was cast between two grease-free glass 
plates (10.6 cm by 10.1 cm and 1.5 mm thickness). The gel mixture was loaded into the 
gap to a height of 7.5 cm. Seventy per cent ethanol was carefully layered over the gel 
mixture to ensure a straight meniscus and to exclude oxygen which inhibits the 
polymerization reaction. 
The gel was allowed to polymerize for approximately 45 min before the ethanol 
was decanted. A 5 % stacking gel (Appendix 5c) was prepared and layered over the 
separation gel with comb in position and allowed to polymerize. The comb was removed 
and the wells were flushed with upper tank running buffer (Appendix 5d) before loading 
the samples.  
Twenty µl of each protein sample and 8 µl of the molecular weight marker 
(Invitrogen, USA) were carefully loaded into each well. The loaded gel assembly was 
immersed into the electrophoresis chamber containing 1 L of lower tank running buffer 
(Appendix 5e). The upper chamber of the gel set up was filled with upper tank buffer 
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(Appendix 5d) to its brim and the electrodes were connected to the power pack (Biorad, 
USA). Electrophoresis was carried out using constant current of 25 mA per gel for 1.5 h.  
 
2.8.3 Western Blotting Analysis 
Upon the completion of SDS-PAGE electrophoresis, the proteins were transferred 
onto a nitrocellulose membrane (BioRad, USA). The transfer was carried out at 400 mA, 
200 volts for 3 h in transfer buffer (Appendix 5f). Blocking step was then carried out to 
saturate the protein binding sites on the nitrocellulose membrane by incubating the 
membrane with 5 % skim milk (Appendix 5g) for 1 h at room temperature.  
The blot was then washed thoroughly with cold PBS (Appendix 1b) to remove all 
traces of milk. The blot was incubated with primary antibody with appropriate dilution 
(Table 2.7) overnight at 4 oC on an orbital shaker. The primary antibody was removed 
and the membrane was washed with wash buffer at room temperature for 5 min. Cold 
PBS (Appendix 1b) was used to remove all traces of detergent on the blot. The membrane 
was then incubated with the appropriate secondary antibody (Table 2.7) for 1 h at room 
temperature. 
The membrane was then washed with wash buffer and cold PBS (Appendix 1b) in 
the similar fashion as above. Nitroblue tetrazolium (NBT), which is a substrate for 
alkaline-phosphatase, was added to develop the protein bands. 
 
Table 2.6 List of antibodies used in Western blotting analysis 
Type of antibody Name Dilution Source 
Primary, polyclonal Rabbit a anti-WNV 1:500 A kind gift from 
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Capsid, Emeritus Professor 
Westaway 
(Australia) 
Primary, polyclonal Rabbit a anti-WNV 
NS2B 




Primary, polyclonal Rabbit a anti-WNV 
NS4B 




Primary, polyclonal Rabbit a anti-WNV 
NS5 






Mouse, anti-actin 1:1000 Chemicon, USA 
Secondary, 
polyclonal 
Goat anti-rabbit Ig  
Alkaline-phoshatase 
conjugated  
3:5000 Chemicon, USA 
Secondary, 
polyclonal 
Goat anti-mouse Ig  
Alkaline-phoshatase 
conjugated 
3:5000 Chemicon, USA 
 





2.9 ELECTRON MICROSCOPY 
2.9.1 Processing for Transmission Electron Microscopy  
Vero cells cultivated in T75 tissue culture flasks with approximately 70 % 
confluent were used for transient transfection and were followed by WNV infections 24 h 
post transfection as described in section 2.2.5. Stably-transfected cells seeded into T75 
flasks overnight to give 90 % confleuncy were used for virus infections. 
At 12- and 24 h p. i., the cell monolayer was washed three times with cold PBS 
(Appendix 1b). The cells were then fixed at 4 oC for 3 h in 4.0 % paraformaldehyde 
(Appendix 6a) and were scraped off the plastic surface with a rubber policeman (Nunc, 
Germany). The cells were transferred into 15 ml tube (Falcon, USA) and were spun 
down. The cells were washed with cold PBS (Appendix 1b) twice and the pellets were 
resuspended in 5 % gelatin. The cells were spun down and the gelatin with the cells was 
allowed to harden at 4 oC for 30 min. The harden blocks were post fixed with the above 
fixative for another 10 min. The blocks were then cut into 1 mm cubes and immersed in 
PBS (Appendix 1b) overnight. The cell cubes were rinsed with ddH2O twice before being 
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Table 2.7 Ethanol concentration and dehydration time 
Ethanol Concentration Dehydration Time 
25 % 5 min  
50 % 10 min 
70 % 10 min 
95 % 10 min 
100 % 30 min (2 X) 
 
The dehydrated cell cubes were then infiltrated using LR white resin (London 
Resin Company, UK) as described in Table 2.9. 
 
Table 2.8 Components and time required for infiltration steps 
Components Infiltration time 
2:1 LR white: absolute ethanol 30 min 
Pure LR white  60 min (2 X) 
Pure LR white 48 h 
Pure LR white 60 min (3 X) 
 
Each cube was then embedded in gelatin capsule filled with LR white resin and 
the resin was allowed to polymerize at 50 oC for about 48 h. The embedded samples were 
sectioned into ultrathin sections of 100 nm in thickness using the ultramicrotome 
(Ultracut E, Reichert-Jung, Germany). The sections were picked up onto 200 mesh 
uncoated copper grid (Taabs, UK) and stained with saturated aqueous uranyl acetate 
(Appendix 6b) for 5 min. The excess stains were washed off using ddH2O. This was 
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followed by second staining with Reynolds lead citrate solution (Appendix 6c) for 
another 8 min. The excess stains were also washed off using ddH2O. The sections were 




















3.1 CLONING HAIRPIN siRNA INSERTS INTO pSILENCER VECTOR 
The NS5 gene sequence of WNV (Sarafend) (GenBank: AY688948) was initially 
used to screen for potential RNAi target site using the software program siRNA Target 
Finder provided by Ambion, USA (Section 2.3.1). The gene sequence was scanned for 
AA dinucleotides sequences that combined with the downstream 19 nt, contained a G/C 
content of approximately 30-50%. The target 5-AAGAACCACAACTGGTGCAGA-3 
was found to be a potential site during this initial screen. The oligonucleotides were 
designed, synthesized and cloned into the pSilencerTM 3.0-H1 (Ambion, USA) expression 
vector. The various clones of bacteria were selected and the plasmids were extracted from 
the E. coli as described in Section 2.3.3. Sequencing reactions were carried out to verify 
the sequence of the inserts. One of the clones selected revealed that the construction of 
pSilencer vector was successful (Figure 3.1a) and the resulting plasmid designated as 
pshNS5-1.  
A negative vector control was constructed and included in this study. The target 
sequence of pshNS5-1 was scrambled using software program InvivoGen's siRNA 
Wizard hosted by Invitrogen, USA at http://www.sirnawizard.com/scrambled.php 
(Table 2.1). The scrambled sequence obtained was 5-
GACGGAACGCCAGCCAATTGA-3 and it shows no homology with monkey or 
human genome. This construct is named as pshNS5scrambled-1 and its insert sequence is 
shown in Figure 3.1b. Both the pshNS5-1 and pshNS5scrambled-1 constructs were then 
scaled up using the QIAGEN Endofree Plasmid Maxi Kit (QIAGEN, USA) as described 







Figure 3.1 Electropherograms showing sequences of the inserts in (a) pshNS5-1 and (b) 
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3.2 TRANSFECTION WITH VECTOR CONSTRUCTS DOES NOT INDUCE 
CYTOTOXICITY 
 After both plasmids pshNS5-1 and pshNS5scrambled-1 were scaled up to a 
workable quantity, they were transfected into the Vero cells grown in 24-well tissue 
culture plates as described in Section 2.4.1. The cells were then incubated at 37 °C for 24 
h to allow the expression of shRNAs. Vero cells that were subjected to similar condition 
in the absence of plasmids were used as negative control. The cells transfected with the 
plasmids were then assessed for cytotoxicity using the CytoTox 96® Non-Radioactive 
Cytotoxicity Assay kit (Promega, USA). The amount of substrate converted to the red 
colorimetric product (formazan) was measured in the form of absorbance (at the 
wavelength 490nm), which is directly proportional to the amount of lactate 
dehydrogenase (LDH) produced in the culture. This in turn is an indication of cell death.  
 As seen in Figure 3.2, the activities of LDH from pshNS5-1- and 
pshNS5scrambled-1-transfected Vero cells were similar to that of non-transfected 
negative control cells. The mean absorbances of the colorimetric products from cultures 
transfected with pshNS5-1, pshNS5scrambled-1 and non-transfected cells were 0.44, 0.25 
and 0.33, respectively. One-way Anova test (SPSS for windows version 12) was 
performed on these data. This tests the hypothesis that several means (absorbance of 
colorimetric products from cells transfected with pshNS5-1 or pshNS5scrambled-1 or 
non-transfected cells) are equal. The F-value generated for between group comparisons 
was 3.127 and has a significance value of 0.088 (P > 0.05). Hence, there is no strong 
evidence that the absorbance of colorimetric products generated from transfections of 
pshNS5-1 or pshNS5scrambled-1 vectors was different from the non-tranfected negative 
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control cells. This illustrated that transfected of pshNS5-1 and pshNS5scrambled-1 



































Figure 3.2 Absorbance of colorimetric products at the wavelength of 490nm. One-way 
Anova test shows that there is no difference in the activities of LDH from cells 
transfected pshNS5-1 and pshNS5scrambled-1 to that of non-transfected negative control 



































3.3 REAL-TIME POLYMERASE CHAIN REACTION 
To determine if the specific siRNA generated from pshNS5-1 construct has a 
direct effect on inhibiting WNV replication at gene level, the amount of WNV viral RNA 
transcripts in pshNS5-1-transfected cells was quantified by real-time PCR. Vero cells 
were transfected with pshNS5-1 and the cells were then subjected to WNV infection at a 
M.O.I. of 10.  At 12- and 24 h p. i., the infected cells were lysed and total RNA was 
harvested as described in Section 2.6.1. West Nile virus E protein gene and β-actin 
mRNA were reverse transcribed and processed for real-time PCR as described in 
Sections 2.6.2 and 2.6.3. β-actin cDNA was used to normalize WNV E transcripts 
number in the real-time PCR. 
In addition, a standard curve was constructed for the quantification of viral 
transcripts from cells transfected and infected with WNV. A pool of WNV was 
concentrated to 1x1010 PFU / ml. Serial dilutions were carried out and the viral RNA was 
extracted. The RNA was reverse transcribed and quantified using real-time PCR (Section 
2.6.3). A standard curve of the threshold cycle (Ct) value against the number of viral 
transcripts was constructed.  
The cells transfected with pshNS5-1 showed a 2.18- and 2.85 log10 unit reduction 
in WNV viral transcripts when compared to the non-transfected, WNV-infected cells at 
12- and 24 h p. i., respectively (Figure 3.3). Independent T-test (SPSS version 12) was 
used to compare the mean log10 unit virus transcripts between these two groups of cells. 
P-values were given as 0.031 and 0.043 (both P < 0.05) at 12- and 24 h p. i., respectively 
which indicated that the mean log10 unit virus transcripts of these two groups of cells are 
different. In contrast, Vero cells transfected with pshNS5scrambled-1 vector control 
showed only 0.41 log10 unit inhibition in WNV E transcripts when compared to non-
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transfected WNV infections at both time points. T-tests gave P-values of 0.62 at both 12- 
and 24 h p. i. revealed that there were no significant differences between these groups of 
cells. Therefore, pshNS5-1 was capable of reducing the amount of viral RNA transcripts 





















































Figure 3.3 Quantification of WNV transcripts by real-time PCR. The threshold cycles 
(Ct) values of the various samples were converted to the number of viral transcripts using 
a standard curve. The log10 inhibition of the viral transcripts is plotted by comparing the 
amount of viral RNA harvested from the vectors (pshNS5-1 and pshNS5scrambled-1)-








  12 h p. i.                            24 h p. i. 
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3.4 IMMUNOFLUORESCENCE STUDIES INDICATE EFFECTIVE SILENCING 
OF WNV-INFECTED VERO CELLS 
Since pshNS5-1 is capable of reducing the number of viral RNA transcripts, the 
expressional level of viral NS5 protein was further assessed to provide confirmation on 
the inhibitory effects of siRNA on WNV infection.  Expression of NS5 protein in WNV-
infected cells were determined by immunofluorescene staining using rabbit polyclonal 
anti-NS5 protein anti-serum and visualized using secondary antibody conjugated to 
FITC. Two hundred cells were counted in each sample and the percentages of fluorescing 
cells were noted.  
A typical perinuclear staining pattern of NS5 protein was observed in Vero cells 
infected with WNV (Figure 3.4a and b-arrows). For WNV-infected cells (not transfected 
with pshNS5-1), at 12- and 24 h p. i., more than 90 % of the cell population were stained 
green using anti-NS5 protein antibody-conjugated to secondary antibody with FITC 
(Figures 3.4a and 3.4b). Cells transfected with pshNS5scrambled-1-infected with WNV 
showed almost the same intensity and frequency of fluorescence as the non-transfected 
wild type WNV-infected cells (Figures 3.4c and 3.4d). Mock-infected, pshNS5-1-
transfected Vero cells acted as negative control yielded no green fluorescence at the two 
time points (Figures 3.4e and 3.4f). This indicated that the anti-sera did not cross-react 
with the Vero cells. 
In comparison to the wild-type WNV-infection (Figure 3.4a), the infected Vero 
cells that were pre-transfected with pshNS5-1 construct displayed a marked decrease in 
intensity and frequency of staining, with less than 10 % of the cell population emitting 
green fluorescence (Figure 3.4g) at 12 h p. i. At 24 h p. i., about 40 % of the pshNS5-1-
transfected cells showed fluorescence (Figure 3.4h) but at a lower intensity when 
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compared to the non-transfected cells. A possible explanation for the increased in the 
fluorescence staining for NS5 proteins observed in the pshNS5-1 transfected cells at 24 h 
p. i. is that transfection efficiency of pshNS5-1 is usually not 100 % and cells which were 























Figure 3.4 Immunofluorescence microscopy images of Vero cells at 12- and 24 h p. i. 
The cells were stained with primary antibody, rabbit anti-NS5 protein polyclonal 
antiserum followed by secondary antibody, anti-rabbit FITC conjugated Ig (Source: 
donkey). (a) and (b): Non-transfected WNV-infected cells with more than 90 % emitting 
green fluorescence at 12- and 24 h p. i., respectively; (c) and (d): pshNS5scrambled-1-
transfected and WNV-infected cells showing similar infection pattern as the wild-type 
WNV infection; (e) and (f): pshNS5-1 transfected, mock-infected cells yielding no 
fluorescence is the negative control; (g) and (h): pshNS5-1-transfected and WNV-
infected cells with less than 10 % and 40 % of cell population emitting green 
fluorescence at 12- and 24 h p. i., respectively.   
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Anti- NS5 antisera 
pshNS5-1 
transfected + WNV- 
infected  
pshNS5-1 
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3.5 DECREASED VIRAL PROTEIN EXPRESSION IN pshNS5-1-
TRANSFECTED VERO CELLS 
To affirm the down-regulation of the expression of WNV viral protein by the 
plasmid-based expressed siRNAs, the expression levels of viral protein NS5 was also 
determined by Western blot detection.  In Figure 3.5, the pshNS5-1 transfected and 
WNV-infected cells showed a drastic decrease in the amount of NS5 protein at 12 h p. i. 
when compared to non-transfected wild-type WNV infection. There was a 4-fold 
decrease in the band intensity using ImageQuant version 5.2 (Molecular Dynamics, 
USA). Cells transfected with pshNS5scrambled-1 vector and infected with WNV showed 
less than 0.2-fold difference in NS5 protein production as compared to wild-type WNV 
infection at 12 h p. i. 
Although at 24 h p. i., there was an increase in the quantity of viral NS5 protein, 
the pshNS5-1-transfected and infected cells still showed 2-folds lower amount of viral 
NS5 protein when compared to the non-transfected WNV infected cells. There was no 
difference in band intensity observed between cells transfected with pshNS5scrambled-1 
vector and the wild-type WNV infection at 24 h p. i. No band was observed for cell lysate 
from mock-infected-pshNS5-1-transfected cells at both time points. Actin was used as a 
loading control to ensure equal amount of proteins were loaded into each well. The 12- 
and 24 h p. i. results correlated well with the previous data gathered from 
immunofluorescence detection of viral protein suggesting that there was indeed an 













Figure 3.5 Reduction of viral NS5 protein expression in pshNS5-1-transfected cells. Cell 
lysates harvested from pshNS5-1-transfected and WNV-infected cells when compared to 
wild-type WNV infection show a 4- and 2-fold reduction in viral NS5 protein production 
at 12- and 24 h p. i., respectively. Cell transfected with pshNS5scrambled-1 do not have 
reduced NS5 production at the two time points. Actin was used as a loading control to 








3.6 DECREASED VIRUS TITRE IN pshNS5-1-TRANSFECTED CELLS 
From the immunofluoresence microscopy result in Figure 3.4, the lack of positive 
fluorescent cells implied a likely decrease in infectious virus particle production. To 
prove this, the supernatants from the transfected and infected cell cultures (Section 2.2.4) 
were collected to determine the virus titres. At 12 h p. i., cells transfected with pshNS5-1 
showed a marked decrease in the titre of virus released as compared to the wild-type 
WNV-infected cells (Figure 3.6). There was a 1.01 log10 unit reduction of infectious virus 
particles produced from pshNS5-1-transfected cells, indicating the ability of the construct 
to interfere with WNV replication. This was substantiated by Independent-samples T-
tests (SPSS version 12) which compared the mean of log10 unit virus of pshNS5-1-
tranfected cells and non-transfected cells. The test yielded a T-value of -7.96 which 
translated to a P-value of 0.001 (P < 0.05). It is therefore highly significant that the mean 
of log10 unit virus of pshNS5-1-transfected cells was different from that of the wild-type 
WNV-infected cells.  
At 24 h p. i., cells transfected with pshNS5-1 still showed a 65% reduction in 
virus titre (Figure 3.6) when compared to wild-type WNV infection. The level of 
decrement, while lower than that of pshNS5-1-transfected cells after 12 h p. i., was still 
enough to demonstrate that there was marked decrease in infectious virus particles 
released. T-test gave a P-value of 0.031 (P < 0.05), indicating that the silencing was still 
effective after 24 h infection. There was a mere 1.4 % difference in the number of virus 
particles produced between the pshNS5scrambled-1-transfected cells and non-transfected 
WNV-infected cells at both time points. T-test indicated there was no significant 















Figure 3.6 Virus titre between transfected and infected Vero cells. pshNS5-1 transfected 
cells reveal a 90 % and 65 % decrease in virus production at 12 h p. i. and 24 h p. i., 
respectively. Cells transfected with the vector control pshNS5scrambled-1 show less than 
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3.7 MORPHOLOGICAL STUDY OF pshNS5-1 TRANSFECTED CELLS USING 
ELECTRON MICROSCOPY 
Transmission electron microscopy (TEM) was used to detect the presence of virus 
particles. For non-transfected WNV-infected cells, more than 80 % of the cells were 
infected with large number of virus (arrows) and were observed budding from the cell 
surfaces (Figure 3. 7a) after 24 h of infection. Vero cells transfected with pshNS5-1 and 
infected with WNV after 12 h infection showed minimal virus particles. After screening 
25 cells, only 3 virus particles were seen budding from a single cell (Figure 3.7b). 
Moreover, the cells transfected with pshNS5-1 appeared healthy with large number of 
intact mitochondria (white arrows) after 12 h of WNV infection (Figure 3.7c). This 
indicated that siRNA process does not seem to interfere with the normal cellular process. 
In addition, there was extensive proliferation of endoplasmic reticulum [(ER) (white 
arrowheads)] seen in the transfected cells. There seems to be built up of virus particles 
after 24 h of infection. However, the number of virus particles was still low as evident 
with 70% of the cell population remaining uninfected. This correlated with the plaque 
assay results (Section 3.3) which showed that there was a 65% reduction in virus titre. 
The low amount of virus particles suggested that siRNA continued to exert its effect on 
the pshNS5-1-tranfected cells, and the assembly of WNV virus is still hindered.  
Cells transfected with pshNS5scrambled-1 and infected with WNV showed 
similar infection patterns to that of non-transfected WNV-infected counterparts. There 
were approximately 40- and 85 % of the cells showing cytopathic effects at 12- (Figure 




Figure 3.7 TEM micrographs of transfected cells infected with WNV (a): More than 80 
% of the non-transfected cells are infected with WNV at 24 h p. i. and virus are budding 
(arrows) at the cell surfaces; (b): Twelve % of the cells transfected with pshNS5-1 and 
infected with WNV show virus (arrow) budding at cell surfaces at 12 h p. i.; (c): Cells 
transfected with pshNS5-1 and infected with WNV with large number of mitochondria 
(white arrows)  and extensive ER (white arrowheads) biogenesis 12 h p. i.;  (d): Vero 
cells transfected with pshNS5scrambled-1 and WNV-infected, similar to non-transfected 
counterparts, are infected in large numbers. Virus (arrows) are budding at surface 










































































3.8 CLONING OLIGONUCLEOTIDE DUPLEXES INTO pSILENCERTM  3.1-H1 
neo VECTOR 
There are multiple guidelines available for selecting and designing siRNA against 
target sites, however the exact criteria needed for designing successful siRNA has not 
been elucidated. Hence, there is a need to scan for various sites and design different 
siRNAs and test out their efficacies in silencing WNV replication.     
The capsid, NS2B and NS4B gene sequences of WNV (Sarafend) (GenBank; 
AY688948) were used to locate potential RNAi target sites using the software program 
siRNA Target Finder provided by Ambion, USA (Section 2.3.1). One target was selected 
from each of these three gene sequences and oligonucleotides duplexes were designed. 
They were then cloned into the vector, pSilencerTM 3.1-H1 neo. Sequencing was then 
carried out to verify the sequence and orientations of the inserts (Figure 3.8a-c). The 
constructs targeting the capsid, NS2B and NS4B genetic sites were designated as 
pshCapsid, pshNS2B and pshNS4B, respectively. The target sequences of these three 
clones were scrambled using the software program InvivoGen's siRNA Wizard 
(Invitrogen, USA) to generate the corresponding scrambled vector controls (Figure 3.8d-
f). They were assigned as pshCapsidscrambled, pshNS2Bscrambled and 
pshNS4Bscrambled. These scrambled vector controls were found to have no homology 







Figure 3.8 Electropherograms showing the sequences of the oligonucleotides into the 
improved version of vector pSilencer 3.1-H1 neo. 
(a) The construct is pshCapsid  
(b) The construct is pshNS2B 
(c) The construct is pshNS4B 
(d) The construct is pshCapsidscrambled 
(e) The construct is pshNS2Bscrambled 





























3.9 TRANSFECTION WITH VECTOR CONSTRUCTS DID NOT INDUCE 
CYTOTOXICITY  
 The various plasmids were scaled up to a workable quantity and were subjected 
to the LDH cytotoxicity test. As previously described, they were transfected into the Vero 
cells grown in 24-well tissue culture plates (described in Section 2.4.1). Vero cells that 
were treated similarly with the transfection agent in the absence of plasmids were used as 
negative control. After incubating at 37 °C for 24 h to allow the expression of shRNAs, 
the cells transfected with the plasmids were then assessed for cytotoxicity using the 
CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega, USA). The amount of 
colorimetric products formed from the activities of LDH was measured.   
For each group (cells transfected with different vector construct), three readings 
of the absorbance of the colorimetric products (Formazan) generated were taken. The 
absorbance of products converted as a result of LDH released from each transfection 
treatment ranged from 0.1 to 0.4, hence accounting for the large standard error observed. 
The amounts of LDH released from the different groups of transfected cells were similar 
to that of negative control cells with the average absorbance ranging from 0.28 to 0.34. 
One-way Anova test gave an F-value of 0.51 and a significance value of 0.81 (P > 0.05) 
hence, there was no evidence showing that the mean absorbance of various group was 
different. This indicated that the presence of vectors in the cells did not further bring on 



































Figure 3.9 Transfection with vector constructs did not induce cytotoxicity. The amounts 
of colorimetric products generated from cells transfected with vector constructs are 














3.10 REAL-TIME POLYMERASE CHAIN REACTION 
As previous, real-time PCR was employed to determine the effect of the siRNAs 
generated from different constructs had on the WNV replication. The cells were 
transfected with plasmids and infected with WNV at M.O.I. of 10.  The infected cells 
were then harvested at 12- and 24 h p. i. and processed for real-time PCR as described in 
Section 2.6.3. The Ct values collected from the real-time PCR experiments were 
normalized using the β-actin gene as an internal control. They were then converted to the 
number of viral transcripts using a standard curve.  
The cells transfected with pshCapsid showed a 4.89- and 5.52-log10 unit reduction 
in WNV viral transcripts when compared to the wild-type infection at 12- and 24 h p. i., 
respectively (Figure 3.10). Statistical analysis was performed by comparing the mean of 
log10 virus transcripts of pshCapsid-transfected cells and non-transfected wild-type 
WNV-infected cells. Independent-samples T-tests (SPSS version 12) gave values of -5.85 
and -5.06 which translated to P-values of 0.004 and 0.007 (both P < 0.05) at 12- and 24 h 
p. i., respectively. It is therefore highly significant that the mean of log10 virus transcripts 
of pshCapsid-transfected cells was different from that of the wild-type WNV-infected 
cells. Cells transfected with pshCapsidscrambled control vector showed a -0.04- and 0.08 
log10 unit inhibition in the number of viral transcript when compared to the wild-type 
WNV-infected cells at the two time points. Independent T-test indicated there was no 
difference in the level of viral RNA transcripts between the two groups. 
Cells transfected with pshNS2B was also effective in reducing the number of 
WNV transcripts. There was a 5.85- and 4.77 log10 unit reduction in the viral genome 
copy number at 12- and 24 h p. i., respectively. T-tests gave P-values of 0.00 and 0.005 
(both P < 0.05) which indicated the presence of strong evidence that the means of log10 
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virus transcripts of pshNS2B-transfected cells were different from that of the wild-type 
WNV-infection at 12- and 24 h p. i. As above, cells transfected with vector control 
pshNS2Bscrambled did not have an inhibitory effect on WNV replication. There was a 
0.75- and 0.55 log10 unit reduction in viral transcripts at the two time points. T-tests gave 
P-values of 0.173 and 0.644 (both P > 0.05) which signified no difference in the mean of 
log10 virus transcripts between pshNS2Bscrambled-transfected cells and non-transfected 
WNV-infected cells.  
From Figure 3.10, cells transfected with pshNS4B showed only 1.47- and 1.23 
log10 unit reduction in viral genome copy number at 12- and 24 h p. i., respectively. The 
amount of reduction in viral transcripts was minimal when compared to that of pshCapsid 
and pshNS2B-transfected cells. T-tests were performed, giving T-value of -2.81 and -
1.49 at the two corresponding time points.  This was translated to P-values of 0.048 (P < 
0.05) at 12 h p. i. and 0.211 (P > 0.05) at 24 h p. i. Therefore, there were some evidence 
that pshNS4B was able to reduce the number of WNV transcripts at 12 h p. i. but not at 
24 h p. i. This may indicate the poor ability of pshNS4B in silencing WNV replication. 
No inhibition was observed from cells transfected with pshNS4Bscrambled vector 
control. At both 12- and 24 h p. i., there were only 0.49- and -0.10 log10 unit reduction in 
viral transcripts. The lack of silencing in viral replication was further confirmed by T-















Figure 3.10 Real-time PCR to show the number of viral transcripts in cells transfected 
with various vectors. Both pshCapsid- and pshNS2B-transfected cells have significantly 
lower viral transcripts at both 12- and 24 h p. i. Cells transfected with pshNS4B has some 
reduction in the number of viral transcripts produce at 12 h p. i. but show no inhibition of 
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3.11 IMMUNOFLUORESCENCE MICROSCOPY TO VISUALISE EFFECT OF 
VECTORS ON WNV REPLICATION IN VERO CELLS 
To further establish the effect of various vectors on WNV replication, 
immunofluorescence microscopy was carried out. The expressional level of different 
viral proteins was assessed. Cells were fixed and stained with different primary 
antibodies followed by secondary antibody conjugated to FITC as stated in Section 2.7. 
Two hundred cells were counted in each sample and the percentages of fluorescing cells 
were noted.  
For cells (non-transfected) infected with WNV, more than 80 % of the population 
were stained green using anti-Capsid protein antibody-conjugated to secondary antibody 
with FITC (Figures 3.11a and 3.11b). Cells transfected with pshCapsidscrambled and 
infected with WNV showed similar infection patterns as the non-transfected wild-type 
WNV-infected cells. The same intensity and frequency of fluorescence were observed 
(Figures 3.11c and 3.11d). Mock-infected, pshCapsid-transfected Vero cells acted as 
negative control yielded no green fluorescence at the two time points (Figures 3.11e 
and3.11f). This indicated that the anti-sera did not cross-react with the Vero cells. 
In comparison to the wild-type WNV-infection (Figure 3.11a), the infected Vero 
cells that were pre-transfected with pshCapsid construct displayed a marked decrease in 
intensity and frequency of staining, with less than 10 % of the cell population emitting 
green fluorescence (Figure 3.11g) at 12 h p. i. At 24 h p. i., the amount of fluorescence in 
pshCapsid-transfected cells was maintained at less than 10 % of the population (Figure 
3.11h). This correlated well to the real-time PCR results showing that the pshCapsid was 
able to sustain the silencing effect on WNV replication.  
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Figure 3.11 Immunofluorescence microscopy images of Vero cells stained for Capsid 
protein at 12- and 24 h p. i. 
The cells were stained with primary antibody, rabbit anti-Capsid polyclonal 
antiserum followed by secondary antibody, anti-rabbit FITC conjugated Ig (Source: 
donkey). (a) and (b): Non-transfected WNV-infected cells with more than 90 % emitting 
green fluorescence; (c) and (d): pshCapsidscrambled-transfected and WNV-infected cells 
showing similar infection pattern as the wild-type WNV infection; (e) and (f): pshCapsid-
transfected, mock-infected cells yield no fluorescence acting as negative control; (g) and 
(h): pshCapsid-transfected and WNV-infected cells with less than 10 % of cell population 









































































Following this, cells transfected with pshNS2B were also tested for the ability to 
silent WNV replication. They were stained with rabbit anti-NS2B antibody (primary 
antibody) to observe infection patterns. As previously seen, cells (non-transfected) 
infected WNV showed a high percentage of infections with more than 90 % of the cell 
population stained green at both 12- and 24 h p. i. (Figures 3.12a and 3.12b). Cells 
transfected with control vector pshNS2Bscrambled and infected with WNV exhibited 
similar infection patterns as the wild-type WNV-infected cells. There were about 90 % of 
the cells that were stained green at both time points (Figures 3.12c and 3.12d). Vero cells 
which were transfected with pshNS2B and mock-infected had no green fluorescence at 
the two time points (Figures 3.12e and3.12f).  
Cells transfected with pshNS2B and infected with WNV displayed a marked 
decrease in intensity and frequency of staining. Less than 10 % of the cell population 
emitted green fluorescence at 12- and 24 h p. i. (Figure 3.12g and 3.12h). This correlated 
well to the real-time PCR results where the pshNS2B construct was able to silence WNV 











Figure 3.12 Immunofluorescence microscopy images of Vero cells stained for NS2B 
protein at 12- and 24 h p. i. 
The cells were stained with primary antibody, rabbit anti-NS2B polyclonal 
antiserum followed by secondary antibody, anti-rabbit FITC conjugated Ig (Source: 
donkey). (a) and (b): Wild-type WNV-infected cells with more than 90 % emitting green 
fluorescence; (c) and (d): pshNS2Bscrambled-transfected cells infected with WNV 
exhibit similar infection pattern as the wild-type WNV infection; (e) and (f): pshNS2B-
transfected, mock-infected cells yielding no fluorescence acting as negative control; (g) 
and (h): pshNS2B-transfected and WNV-infected cells with less than 10 % of cell 


















         12 h p. i.                                      24 h p. i. 










transfected + WNV 
infected 
pshNS2B transfected + 
mock-infected 




            The NS4B region of the WNV genome was next targeted and Vero cells were 
transfected with the construct pshNS4B. They were stained with rabbit anti-NS4B 
antibody (primary antibody) to observe for silencing effect in the virus replication. As 
before, a large number of the non-transfected WNV -infected cells showed signs of virus 
replication. Almost 100 % of the cell population was stained green at both 12- and 24 h p. 
i. (Figures 3.13a and 3.13b). Similar infection rate was observed for cells transfected with 
control vector pshNS4Bscrambled and infected with WNV where there were more than 
90 % of the cells staining green at both time points (Figures 3.13c and 3.13d).  No green 
fluorescence was noted in cells transfected with pshNS4B and mock-infected (Figures 
3.13e and 3.13f). 
Cells transfected with pshNS4B and infected with WNV displayed a slightly 
lower degree of infection at 12 h p .i with 50 % of the cells staining green (Figure 3.13 g). 
However at 24 h p. i., almost 90 % of the cells were stained green. (Figure 3.12h). This 
showed that there was no sustained silencing effect on virus replication by the plasmid 
pshNS4B. This set of data correlated well to the real-time PCR results where the 










Figure 3.13 Immunofluorescence microscopy images of Vero cells stained for NS4B 
protein at 12- and 24 h p. i. 
The cells were stained with primary antibody, rabbit anti-NS4B polyclonal 
antiserum followed by secondary antibody, anti-rabbit FITC conjugated Ig (Source: 
donkey). (a) and (b): Almost all the non-transfected cells are infected with WNV as 
indicated by the green fluorescence; (c) and (d): pshNS4Bscrambled-transfected cells and 
infected with WNV exhibit similar infection pattern as the wild-type WNV infection; (e) 
and (f): pshNS4B transfected, mock-infected cells yielding no fluorescence act as 
negative control; (g) and (h): 50 % of the pshNS4B-transfected and WNV-infected cells 
emitting green fluorescence at both 12 h p. i. while more than 90 % of the same group of 
cells producing green fluorescence at 24 h p. i.    
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3.12 DETECTION OF VIRAL PROTEIN EXPRESSIONS IN VECTORS 
TRANSFECTED VERO CELLS 
Western blots were carried out to detect the expression of viral proteins, an 
indication of virus replication in vector-transfected Vero cells after they were infected 
with WNV. In Figure 3.14, the pshCapsid transfected and infected cells showed a drastic 
decrease in the level of capsid protein at both 12- and 24 h p. i. when compared to non-
transfected wild-type WNV infection. There was a 5- and 10-folds reduction in the band 
intensity at 12- and 24 h p. i., respectively. This showed that there was a continuous 
inhibition of virus protein expression which indicated a sustained silencing of WNV 
replication, thereby correlating well to previous data (Sections 3.10 and 3.11).  
Cells transfected with pshCapsidscrambled vector and infected with WNV had 
only about 0.15-fold different in core protein production as compared to wild-type WNV 
infection at the two time points. This illustrated that the presence of control vector 
pshCapsidscrambled in the Vero cells prior to WNV infection did not inhibit virus 
replication and the silencing effect observed in pshCapsid-transfected cells was sequence 
specific.  
No band was observed for cell lysate from mock-infected-pshCapsid transfected 
cells at both time points. Actin was used as a loading control to ensure equal amount of 















Figure 3.14 Reduction of viral capsid protein expression in pshCapsid-transfected cells at 
both 12- and 24 h p. i. Cell lysates harvested from pshCapsid-transfected and WNV-
infected cells show a 5- and 10-folds reduction in viral capsid protein production at 12- 
and 24 h p. i., respectively when compared to wild-type WNV infection. Cells transfected 
with control plasmid pshCapsidscrambled and infected with WNV show no significant 
differences in capsid production from the wild-type WNV-infected cells at the two time 
points. Actin was used as a loading control to ensure equal amounts of cell lysates were 






Next in Figure 3.15, comparable observations were made to cells transfected with 
pshNS2B and infected with WNV. There was a 6- and 5-fold decrease in the level of 
NS2B protein at 12- and 24 h p. i., respectively when compared to non-transfected wild-
type WNV infection. This verified real-time PCR and immunofluorescence results where 
there were an incessant inhibition of viral NS2B protein expression and hence a 
continuous silencing of WNV replication.  
Cells transfected with pshNS2Bscrambled construct and infected with WNV 
showed no significant difference in the amount of NS2B protein expressions as compared 
to wild-type WNV infection at the two time points. There was less than 0.10-fold 
difference in NS2B protein expression between the two groups of cells at both time 
points.  This concurred with the fact that silencing of virus using RNAi pathway was 
sequence specific.  
  Cell lysates collected from mock-infected-pshNS2B-transfected cells which 
acted as negative control showed no band at both time points. As previously described, 
actin was used to act as a loading control to ensure equal amounts of proteins were loaded 




















Figure 3.15 Decreased levels of viral NS2B protein expression in pshNS2B-transfected 
cells at both 12- and 24 h p. i. Cell lysates harvested from pshNS2B-transfected and 
WNV-infected cells, when compared to non-transfected WNV-infected cells, revealed a 
6- and 5-folds reduction in viral NS2B protein synthesis at 12- and 24 h p. i., 
respectively. Cell transfected with pshNS2Bscrambled and infected with WNV show no 
significant differences in NS2B protein production from the wild-type WNV-infected 
cells at the same time points. Negative control cell lysate harvested from mock-infected 
pshNS2B-transfected cell show no expression of viral proteins. Actin was used as a 






Figure 3.16 illustrated the amount of NS4B protein expressed in different groups 
of cells. Cells transfected with pshNS4B and infected with WNV had an increased in the 
amount of viral NS4B protein production from 12- to 24 h p. i. The cell lysate collected 
this group of cells revealed only a 3-fold reduction and almost no difference in NS4B 
protein expression when compared to wild-type WNV-infected cells at 12- and 24 h p. i., 
respectively. This affirmed earlier findings that pshNS4B construct was not able to 
silence WNV replication effectively. A possible explanation of this non-sustained 
silencing is that very few cells were transfected with the pshNS4B construct and virus 
was replicating well in the susceptible non-transfected cells. The other explanation is that 
the NS4B siRNA target sequence is not an efficient silencer. 
Cells transfected with pshNS4scrambled construct and infected with WNV 
showed about only 0.3- and 0.25-folds difference in NS4B protein expression when 
measured against the non-transfected WNV-infected cells at 12- and 24 h p. i., 
correspondingly. Cell lysate collected from mock-infected-pshNS4B-transfected cells 
which acted as negative control showed no band at both time points. As previous, actin 


























Figure 3.16 Increasing level of expression of viral NS4B protein in pshNS4B-transfected 
cells from 12- to 24 h p. i. Cell lysates harvested from pshNS4B-transfected and WNV-
infected cells, when compared to non-transfected WNV-infected cells, reveal a 3-fold 
reduction and no difference in viral NS4B protein synthesis at 12- and 24 h p. i., 
respectively. Cells transfected with pshNS4Bscrambled and infected with WNV 
expressed similar amount of NS4B protein as the wild-type WNV-infected cells at the 
same time points. Negative control cell lysate harvested from mock-infected pshNS4B-
transfected cell yielded no viral NS4B protein. Actin was used as a loading control to 








3.13 PLAQUE ASSAY TO ASSESS THE PRODUCTION OF INFECTIOUS 
VIRUS PARTICELS  
Plaque assays were carried out to assess the production of infectious virus 
particles from vectors-transfected cells. From the immunofluoresence microscopy result 
in Figure 3.11, the lack of fluorescence in pshCapsid-transfected and WNV-infected cells 
is likely to imply a decrease in infectious virus particle production. Supernatants from the 
transfected and infected cell cultures (Section 2.2.4) were collected to determine the virus 
titre. At both 12- and 24 h p. i., pshCapsid-transfected cells showed a 2- and 1.86 log10 
unit decrease in the titre of virus released as compared to the wild-type WNV-infected 
cells (Figure 3.17). Independent sample T-tests gave  a P-value of 0.003 and 0.000 (both 
p < 0.05) at the two time points, hence indicating a strong evidence that the means of 
log10 virus production from these two groups of cells were different. Therefore, 
pshCapsid was able to interfere with WNV replication effectively.  
 There was no indication of inhibition of virus production from cells 
transfected with pshCapsidscrambled and infected with WNV as shown by a 0.07- and 
0.11 log10 unit difference in virus production when compared to non-transfected WNV-
infected cell at 12- and 24 h p. i., respectively. The T-tests which gave P-values of 0.83 
and 0.125 (both P > 0.05) confirmed these set of data.      
Similarly, pshNS2B-transfected cells were tested for the productivity of infectious 
progeny viruses. These cells showed a 2.37- and 1.87 log10 unit reduction in the number 
of virus particles produced when compared to wild-type WNV infection at 12- and 24 h 
p. i., respectively (Figure 3.17). T-tests revealed P-values of 0.00 (P < 0.05) for the mean 
log10 virus particles of these two groups of cells at the two time points, hence indicating 
that there was a true difference in the mean log10 virus particles between the pshNS2B-
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transfected and non-transfected cells. Therefore, pshNS2B was able to disrupt WNV 
replication, which correlated well to the real-time PCR and proteomics analysis.  
 As previously described, pshNS2Bscrambled vector did not interfere with WNV 
replication. There was 0.08- and 0.05 log10 unit difference in the number of virus 
particles produced when compared to wild-type WNV infection at 12- and 24 h p. i., 
respectively. T-tests which gave P-values of 0.78 and 0.73 (P > 0.05) suggested that the 
average log10 virus particles produced by these two groups of cells were not significantly 
different.   
Real-time PCR and protein expression analysis showed that Vero cells transfected 
with pshNS4B were not able to sustain silencing of WNV replication, hence the 
possibility to suggest the lack of prolonged inhibition of virus production. As expected, 
these cells showed a 1.37- and 0.19 log10 unit decrease in the number of virus particles 
produced when compared to wild-type WNV infection at 12- and 24 h p. i., respectively 
(Figure 3.17). T-tests revealed that the mean of log10 virus production for pshNS4B-
transfected and non-transfected cells was different at 12 h p. i. (P = 0.015) but not at 24 h 
p. i. (P = 0.144). 
  As before, the control vector pshNS4Bscrambled did not inhibit WNV 
replication. The pshNS4Bscrambled transfected cells had only 0.04- and 0.08 log10 unit 
difference in the number of virus particles produced when compared to the non-
transfected WNV-infected cells at 12- and 24 h p. i., respectively. T-tests which gave P-
values of 0.61 and 0.31 (both P > 0.05) suggested that the average log10 virus particles 


















Figure 3.17 Plaque assay revealing the log10 unit inhibition of infectious virus particles 
production in various vectors transfected cells. Both pshCapsid- and pshNS2B-
transfected cells have significantly lower viral titres at both 12- and 24 h p. i. Cells 
transfected with pshNS4B has some reduction in the number of virus progeny produced 














































  . i.                                   24 h p. i. 
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3.14 TRANSMISSION ELECTRON MICROSCOPY TO ASSESS THE 
MORHPHOLOGY OF VECTORS-TRANSFECTED CELLS  
Transmission electron microscopy was used to detect the presence of virus 
particles as well as to visualize the morphology of the cells. A large population of non-
transfected wild-type WNV-infected cells was infected and virus particles (arrows) were 
seen budding at the cell surfaces at both 12- and 24 h p. i. (Figure 3.18).     
Vero cells transfected with pshCapsid and infected with WNV showed minimal 
infection rate at both 12- and 24 h p. i. with less than 10 % of the cells showing signs of 
infection. However, no virus particle was found after screening 100 cells. Most of the 
cells appeared to be healthy with numerous mitochondria, indicating that siRNA process 
does not interfere with normal cellular processes. Similar to the pshNS5-1 transfected 
cells, these cells had extensive ER proliferation (Figure 3.19a - white arrowheads) in the 
cytoplasm which was lacking in the non-transfected cells (Figure 3.18).  
Cells transfected with pshCapsidscrambled were comparable to those of non-
transfected WNV-infected cells. These cells showed high infection rate with numerous 
WNV particles (arrows) budding out at cell surfaces at the two time points (Figure 
3.19b). This was consistent with the other experimental data that these cells were not able 
to inhibit WNV replication. Similarly, pshCapsidscrambled-transfected cells were 
observed to have large amount of ER proliferation in the cytosol (data not shown). Vero 
cells transfected with pshCapsid and mock-infected acted as negative control (Figure 
3.19c). These cells displayed normal cell morphology with numerous mitochondria. In 





















Figure 3.18 TEM micrograph of non-transfected Vero cells infected with WNV with 















cells. The large amount of ER proliferation in the cells is most likely induced by the 
transfection process as it is only present in the transfected cells.   
Cells transfected with pshNS2B were able to disrupt WNV replication as 
observed by the low infection rate under the electron microscope. Consistent with the 
observations made in immunofluorescence mircroscopy, only approximately 10 % of the 
population presented with signs of infections (integrity of cell compromised with no virus 
seen) at both 12- and 24 h p. i. Most of the cells appeared to be normal while only four 
out of the hundred cells screened showed virus (arrow) budding at the cell surface 
membranes (Figure 3.20a). Similar to other transfected cells, these cells had large amount 
of ER proliferation in the cytoplasm (not shown).  
As previously described, cells transfected with pshNS2Bscrambled exhibited high 
infection rate with 90 % of the cells showing cytopathic effects after 24 h of infection. 
Numerous virus particles were seen budding out at cell surfaces at the two time points 
(Figure 3.20b). Similarly, pshNS2Bscrambled-transfected cells displayed large amount of 
ER proliferation in the cytosol (data not shown). Vero cells transfected with pshNS2B 
and mock-infected acted as negative control (Figure 3.20c). These cells had large amount 
of ER proliferation (white arrowheads) in the cytosol otherwise, displaying normal cell 
morphology with numerous mitochondria.  
Small interfering RNAs generated from pshNS4B were not able to produce strong 
inhibition on WNV replication (Section 3.10  3.13) and similar trend was observed 
under the TEM. After 12 h of infection, 45 % of the Vero cells transfected with pshNS4B 
and infected with WNV showed signs of infections (Figure 3.21a). Subsequently, there 
was increasing infection as evident by 24 h p. i. comparable to that of non-transfected 
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Figure 3.19 TEM micrographs of transfected cells (a): Large amount of ER proliferation 
(white arrowheads) in the pshCapsid-transfected and WNV-infected cells at 24 h p. i.; 
(b): Cells transfected with pshCapsidscrambled were infected by WNV with virus 
(arrows) budding from cell surface after 24 h of infection; (c): Vero cells transfected with 
pshCapsid and mock-infected acting as negative control showing numerous mitochondria 







































































Figure 3.20 TEM micrographs of transfected cells (a): Only four out of one hundred 
pshNS2B-transfected and WNV-infected cells show virus budding (arrow) at 24 h p. i.; 
(b): Cells transfected with pshNS2Bscrambled are efficiently infected by WNV with 
numerous virus particles (arrows) budding from cell surface after 12 h of infection; (c): 
Vero cells transfected with pshNS2B and mock-infected acting as negative control 
showing numerous mitochondria and ER proliferations (white arrowheads). The bars in 































































WNV- infected cells (Figure 3.21b). Pronounced ER proliferation (white arrowhead) was 
observed in the cytoplasm of this group of cells. 
Similar to non-transfected counterparts, cells transfected with vector control 
pshNS4Bscrambled and infected with WNV were observed to have numerous virus 
particles budding out at cell surfaces at the 12- and 24 h p. i. (Figure 3.21c). These cells 
have large amount of ER proliferation (white arrowheads) in the cytosol just like the 
other transfected cells. Vero cells transfected with pshNS4B and mock-infected acted as 
negative control (data not shown). They displayed normal cell morphology with 

















Figure 3.21 TEM micrographs of transfected cells (a): Forty-five percent of pshNS4B 
transfected and WNV-infected cells show cytopathic effects at 12 h p. i. with virus 
budding (arrows) at the cell surfaces. ER proliferations in the cytosol are indicated by 
white arrowheads; (b): Cells transfected with pshNS4B were vastly infected by WNV 
with numerous virus particles (arrows) budding from cell surface after 24 h of infection. 
ER proliferations within the cells are illustrated by white arrowheads; (c): Vero cells 
transfected with pshNS4Bscrambled and WNV-infected, are similar to non-transfected 
counterparts. They are highly infected and virus budding at surface membrane (arrows) 
are observed. Endoplasmic reticulum proliferations in the cytoplasm are indicated by 
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3.15 CLONING NS5 HAIRPIN siRNA INSERTS INTO pSILENCERTM 3.1-H1 
Cells transfected with various vectors showed different degrees of ability to 
silence WNV replication. Although cells transfected with pshCapsid and pshNS2B 
showed the greatest silencing effects on WNV replication, there was no total inhibition of 
virus replication. There were decreases in the log10 unit reduction of virus particles 
produced from 12- to 24 h p. i. for these two groups of cells. Similarly, cells transfected 
with pshNS4B and pshNS5 did not produce a sustained inhibition of virus reproduction. 
There was also an increase in the number of virus particles produced from 12- to 24 h p. 
i.  
A few possibilities arise to explain these observations. The first possibility is that 
not all the cells were transfected hence those non-transfected cells could be infected with 
WNV and allowed virus replication. The progeny virus then went on to infect 
neighbouring non-transfected cells, resulting in the increased in the number of virus 
particles. Second possibility is that the rate that the siRNAs were generated from the 
vectors was limiting. The transfected cells were infected with WNV 24 h after 
transfections and there could be a time lag in the transcription and processing of shRNAs, 
therefore could not effectively inhibit the entire virus replication. Other possibility could 
be that different siRNAs targeting at the various regions of the viral genome sequence 
have varying ability to bind to its complementary site, thus resulting in the dissimilarity 
of the silencing effects observed. 
To find out if the lack of complete inhibition on virus replication was due to the 
non-homogenous population of transfected cells, it was decided to produce a stable cell 
line which expressed the shRNAs constitutively. In order to do so, shRNA 
oligonucleotides needed to be cloned into the pSilencerTM3.1-H1 vector that allowed 
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selection of positively-transfected cells and maintenance in the cells. As mentioned in the 
Section 2.3.1, almost all the shRNAs oligonucleotides were cloned into this vector to 
allow creation of stable cell lines. However, the shRNAs oligonucleotides for pshN5-1 
and pshNS5scrambled-1 were cloned into the older version which does not allow 
selection. Therefore, the same oligonucleotides were cloned into the improved version of 
the vector. The constructs were designated as pshNS5 and pshNS5scrambled (Figure 3.22 
a and b). Both the pshNS5 and pshNS5scrambled constructs were then scaled up using 























Figure 3.22 Electropherograms showing sequences of the inserts in (a) pshNS5 and (b) 












 200  
Results 
 103
3.16 STABLE TRANSFECTION WITH VECTOR CONSTRUCTS DID NOT 
INDUCE CYTOTOXICITY 
 Vero cells were transfected with various vector constructs (all shRNA 
oligonucleotides cloned into pSilencerTM3.1-H1 vector) and G418 at a concentration of 
400 µg / ml was used to select positively-transfected cells. After obtaining the stably-
shRNAs expressing cell lines, they were tested if continuous presence of the plasmids 
induced cell cytotoxicity. Non-transfected Vero cells were used as negative control. The 
equal number of cells were seeded and incubated at 37 °C for 24 h before carrying out the 
assessment using the CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega, 
USA). The amount of colorimetric products generated from the activities of LDH was 
measured.   
Three readings of the absorbance of the colorimetric products formed were 
obtained from each stably-transfected cell lines. The absorbance of colorimetric products 
(Formazan) converted as a result of LDH released from each cell line ranged from 0.2 to 
0.6, hence accounting for the large standard error observed (Figure 3.23). The amounts of 
LDH released from the different stably-transfected cell lines were similar to that of 
negative control cells with the average absorbance ranged from 0.25 to 0.65. One-way 
Anova test gave an F-value of 0.206 and a significance value of 0.99 (P > 0.05) hence, 
there was no evidence showing that the mean absorbance of various groups were 
different. This indicated that the presence of vectors continuously in the cells did not 



































Figure 3.23 Cell lines with stably-transfected vector constructs do not induce 
cytotoxicity. The amounts of colorimetric products generated from different stably 












3.17 REAL-TIME POLYMERASE CHAIN REACTIONS TO DETERMINE THE 
COPY NUMBER OF WNV VIRAL TRANSCRIPTS 
Stably-transfected cells were subjected to WNV infection at the M. O. I. of 10. 
Real-time PCR was employed to determine the effect of constitutive expression of 
siRNAs had on the WNV replication. The infected cells were then harvested at 12- and 
24 h p. i. and processed for real-time PCR as described in Section 2.6.3. As previously 
described, the Ct values collected from the real-time PCR experiments were normalized 
using the β-actin gene as an internal control. They were then converted to the number of 
viral transcripts using a standard curve.  
Stable cell line created by transfecting with pshCapsid showed 4.11- and 4.58 
log10 unit reduction in WNV viral transcripts when compared to the wild-type infection at 
12- and 24 h p. i., respectively (Figure 3.24). T-tests gave P- values of 0.006 and 0.001 
(both P < 0.05) when the mean of log10 virus transcripts of stably-pshCapsid-transfected 
cells was compared to that of the non-transfected wild-type WNV-infected cells at 12- 
and 24 h p. i., respectively. It was therefore highly significant that the mean of log10 virus 
transcripts of pshCapsid-transfected cells was different from that of the wild-type WNV-
infected cells. Cells stably-transfected with pshCapsidscrambled control vector showed 
0.29- and 0.41 log10 unit difference in the number of viral transcript when compared to 
the wild-type WNV-infected cells at the two time points. T-test indicated there was no 
difference in the level of viral RNA transcripts between the two groups. 
Cells stably-transfected with pshNS2B had 4.67- and 4.40 log10 unit reduction in 
the viral genome copy number at 12- and 24 h p. i., respectively when compared to non-
transfected WNV-infected cells. There was strong evidence that the average log10 virus 
transcripts of pshNS2B stably-transfected cells were different from that of the wild-type 
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WNV-infections (T-tests gave P-values of 0.00 and 0.001 for the two time points). As 
above, cells stably-transfected with vector control pshNS2Bscrambled did not have an 
inhibitory effect on WNV replication. There was merely 0.10- and 0.28 log10 unit 
difference in viral transcripts 12- and 24 h p. i., respectively. T-tests gave P-values of 
0.582 and 0.523 (both P > 0.05) which signified no difference in the mean log10 virus 
transcripts between pshNS2Bscrambled transfected cells and non-transfected WNV-
infected cells.  
From Figure 3.24, cells stably-transfected with pshNS4B showed 3.81- and 0.93 
log10 unit reduction in viral genome copy number at 12- and 24 h p. i., respectively. T-
tests were performed, giving P-values of 0.033 (P < 0.05) at 12 h p. i. and 0.693 (P > 
0.05) at 24 h p. i. Therefore, pshNS4B was able to reduce the number of WNV transcripts 
at 12 h p. i. but not at 24 h p. i. This indicated that pshNS4B could not maintain the 
silencing effects on WNV replication. Cells stably-transfected with pshNS4Bscrambled 
vector control did not show inhibition on viral replication. At both 12- and 24 h p. i., 
there were only 0.17- and 0.27 log10 unit difference in the amount of viral transcripts 
when compared to wild-type infection. T-tests gave the P-values of 0.86 and 0.52 (both P 
> 0.05) confirmed that there was no significant difference in the mean log10 viral 
transcripts between these two groups of cells. 
Cell line stably-transfected with pshNS5 showed 0.90- and 0.85 log10 unit 
reduction in WNV viral transcripts when compared to the non-transfected WNV-
infection at 12- and 24 h p. i., respectively (Figure 3.24). T-tests which gave P- values of 
0.43 and 0.19 (both P > 0.05) at both time points. There was no significant difference in 
the average log10 virus transcripts of stably pshNS5-transfected cells when compared to 
that of the non-transfected wild-type WNV-infected cells. These cells stably-transfected 
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with pshNS5 were unable to silent WNV replication. Cells stably-transfected with 
pshNS5scrambled control vector showed 0.50- and 0.31 log10 unit difference in the 
number of viral transcript when compared to the wild-type WNV-infected cells at the two 
time points. T-test indicated there was no difference in the level of viral RNA transcripts 























































Figure 3.24 Real-time PCR to show the number of viral transcripts in cells stably-
transfected with various vectors. Both pshCapsid and pshNS2B stably-transfected cells 
had significant lower viral transcripts at both 12- and 24 h p. i. Cells stably-transfected 
with pshNS4B has some reduction in the number of viral transcripts produce at 12 h p. i. 
but shows no inhibition of viral transcripts production at 24 h p. i. Vero cells stably-
transfected with pshNS5 shows no significant reduction in the number of viral transcripts 
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3.18 IMMUNOFLUORESCENCE MICROSCOPY TO ASSESS INFECTION 
PATTERN OF VERO CELLS STABLY-TRANSFECTED WITH VECTORS AND 
INFECTED WITH WNV 
Immunofluorescence microscopy was carried out to assess the effect of 
constitutively expressing shRNAs from stably-transfected cell lines had on WNV 
replication. The expression levels of different viral proteins were assessed and the 
percentage of the fluorescing cells noted.  
The cells that were infected with WNV and expressed Capsid protein were stained 
green using primary anti-Capsid antibody and secondary antibody conjugated to FITC. 
More than 85% of the non-transfected, wild-type infected cells were stained green 
indicating the high percentage of WNV replication at both 12- and 24 h p. i. (Figures 
3.25a and 3.25b). Cells stably-transfected with pshCapsidscrambled and infected with 
WNV were noted to have identical infection patterns as the non-transfected wild-type 
WNV-infected cells as indicated by the same intensity and frequency of fluorescence 
(Figures 3.25c and 3.25d). Vero cells which were stably-transfected with pshCapsid and 
mock-infected acted as negative control and yielded no green fluorescence at the two 
time points (Figures 3.25e and3.25f).  
The infected Vero cells that were stably-transfected with the pshCapsid construct 
exhibited a significant decrease in intensity and frequency of staining when compared to 
the wild-type WNV infection. Only 5 % of the cell population emitted green fluorescence 
(Figure 3.25g) at 12 h p. i. and this cell line maintained the fluorescence level at less than 
10 % of the population exhibiting fluorescence (Figure 3.25h) at 24 h p. i. This correlated 
well to the real-time PCR results showing that the pshCapsid was able to sustain the 
silencing effect on WNV replication.  
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Figure 3.25 Immunofluorescence microscopy images of Vero cells stained for Capsid 
protein at 12- and 24 h p. i. 
The cells were stained with primary antibody (rabbit anti-Capsid polyclonal 
antiserum) followed by secondary antibody, anti-rabbit FITC conjugated Ig (Source: 
donkey). (a) and (b): Non-transfected WNV-infected cells with more than 85 % emitting 
green fluorescence; (c) and (d): pshCapsidscrambled stably-transfected and WNV-
infected cells showing identical infection pattern as the wild-type WNV infection; (e) and 
(f): pshCapsid stably-transfected, mock-infected cells yielding no fluorescence acting as 
negative control; (g) and (h): pshCapsid stably-transfected and WNV-infected cells with 
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Cells stably-transfected with pshNS2B was stained with rabbit anti-NS2B 
antibody (primary antibody) to visualise the infection pattern. More than 90 % of the 
non-transfected wild-type WNV-infected cell population was stained green at both 12- 
and 24 h p. i. (Figures 3.26a and 3.26b), indicating the high replication efficiency of the 
virus. Cells stably-transfected with control vector pshNS2Bscrambled and infected with 
WNV were noted to show similar infection trends as the wild-type WNV-infected cells 
with 92 % of the cells emitting green fluorescence at both time points (Figures 3.26c and 
3.26d). Vero cells which were transfected with pshNS2B and mock-infected had no green 
fluorescence at the two time points (Figures 3.26e and3.26f).  
Cells stably-transfected with pshNS2B and infected with WNV displayed a 
marked decrease in intensity and frequency of staining. Three- and 8 % of the cell 
population were stained green at 12- and 24 h p. i., respectively (Figure 3.26g and 3.26h). 
This correlated well to the real-time PCR results where the pshNS2B construct was able 












Figure 3.26 Immunofluorescence microscopy images of Vero cells stained for NS2B 
protein at 12- and 24 h p. i. 
The cells were stained with primary antibody, rabbit anti-NS2B polyclonal 
antiserum followed by secondary antibody, anti-rabbit FITC conjugated Ig (Source: 
donkey). (a) and (b): Wild-type WNV-infected cells with more than 90 % emitting green 
fluorescence; (c) and (d): pshNS2Bscrambled stably-transfected cells infected with WNV 
exhibited similar infection pattern as the wild-type WNV infection; (e) and (f): pshNS2B 
stably-transfected, mock-infected cells yielding no fluorescence acting as negative 
control; (g) and (h): pshNS2B stably-transfected and WNV-infected cells with less than 
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Following this, Vero cells were stably-transfected with the construct pshNS4B 
and assessed for the ability to sustain silencing WNV replication. They were stained with 
rabbit anti-NS4B antibody (primary antibody) to visualise the expression of NS4B 
protein in the cells. Similarly to previous observations, almost all the non-transfected 
WNV-infected cells were stained green at both 12- and 24 h p. i., demonstrating the rapid 
virus replication in the cells (Figures 3.27a and 3.27b). Vero cells stably-transfected with 
control vector pshNS4Bscrambled and infected with WNV exhibited comparable 
infection patterns where there were 96 % of the cells stained green at both time points 
(Figures 3.27c and 3.27d).  No green fluorescence was noted in cells stably-transfected 
with pshNS4B and mock-infected (Figures 3.27e and 3.27f). 
Cells stably-transfected with pshNS4B and infected with WNV displayed a 
significant decrease in infection rate at 12 h p .i with only 10 % of the cells stained green 
(Figure 3.27g). However this silencing effect was not maintained for long as observed at 
24 h p. i., 86 % of the cells were stained green. (Figure 3.27h). Hence, this set of data 
correlated well to the real-time PCR results where the shRNAs produced by the plasmid 
pshNS4B were not capable in sustaining the silencing effect on WNV replication. This 
trend observed in the stably-transfected cells were similar to that of the transiently- 
transfected cells. Hence, this could be an indication that the plasmid has an instrinsic 







Figure 3.27 Immunofluorescence microscopy images of Vero cells stained for NS4B 
protein at 12- and 24 h p. i. 
The cells were stained with primary antibody, rabbit anti-NS4B polyclonal 
antiserum followed by secondary antibody, anti-rabbit FITC conjugated Ig (Source: 
donkey). (a) and (b): Almost all the non-transfected cells are infected with WNV as 
indicated by the green fluorescence; (c) and (d): pshNS4Bscrambled stably-transfected 
cells infected with WNV exhibit similar infection pattern as the wild-type WNV 
infection; (e) and (f): pshNS4B stably-transfected, mock-infected cells yielding no 
fluorescence acting as negative control; (g) and (h): 10 % of the pshNS4B stably-
transfected and WNV-infected cells emitting green fluorescence at 12 h p. i. whereas 86 

















































Lastly, cells stably-transfected with pshNS5 were evaluated for its ability to 
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silence WNV replication. The cells were stained for the presence of viral NS5 proteins 
using primary anti-NS5 antibody. For non-transfected WNV-infected cells, at 12- and 24 
h p. i., more than 90 % of the cell population was stained green (Figures 3.28a and 
3.28b). Cells stably-transfected with pshNS5scrambled and infected with WNV showed 
no significant difference in the intensity and frequency of fluorescence as the non-
transfected wild type WNV-infected cells (Figures 3.28c and 3.28d). Vero cells stably-
transfected with pshNS5 which were mock-infected acted as negative control yielded no 
green fluorescence at both time points (Figures 3.28e and3.28f).  
As predicted from the real-time PCR results, infected Vero cells that were stably 
transfected with pshNS5 exhibit similar infection trends as the non-transfected wild-type 
WNV infections. Approximately 90 % of the cells were emitting green fluorescence at 
both 12- and 24 h p. i. (Figure 3.28g and 3.28h). It was apparent that shRNAs produced 
from the pshNS5 construct could not effectively produce a silencing effect in the virus 












Figure 3.28 Immunofluorescence microscopy images of Vero cells stained for NS5 
proteins at 12- and 24 h p. i. 
The cells were stained with primary antibody, rabbit anti-NS5 polyclonal antiserum 
followed by secondary antibody, anti-rabbit FITC conjugated Ig (Source: donkey). (a) 
and (b): Non-transfected WNV-infected cells with more than 90 % emitting green 
fluorescence; (c) and (d): pshNS5scrambled stably-transfected and WNV-infected cells 
showing similar infection pattern as the wild-type WNV infection; (e) and (f): pshNS5 
stably-transfected, mock-infected cells yielding no fluorescence acts as negative control; 
(g) and (h): pshNS5 stably-transfected and WNV-infected cells with 90 % of the cell 
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3.19 WESTERN BLOT ANALYSIS OF VIRAL PROTEIN EXPRESSIONS IN 
VERO CELLS STABLY-TRANSFECTED WITH VECTORS 
To confirm the results obtained from real-time PCR and immunofluorescence 
microscopy, western blot analyse were carried out to study the expressions of viral 
proteins in Vero cells stably-transfected with various vector constructs and infected with 
WNV.  As expected to correlated to the previous data (Section 3.17 and 3.18), cells 
stably-transfected with pshCapsid and infected with WNV showed a significant reduction 
in the level of capsid protein expressed when compared to wild-type WNV infections 
(Figure 3.29). There was an 8- and 12- folds decrease in band intensity at 12- and 24 h p. 
i., respectively. Hence, there was a continuous inhibition of virus protein expression 
which is translated to a sustained silencing of WNV replication.  
Cells stably-transfected with pshCapsidscrambled plasmid and infected with 
WNV showed inconsequential difference of less than 0.15-fold in the production of 
capsid protein as compared to wild-type WNV infections at both time points. This 
demonstrated that the shRNAs generated from the control vector pshCapsidscrambled did 
not interfere with WNV replication. No band was observed for cell lysate harvested from 
mock-infected-pshCapsid stably-transfected cells at both time points. Actin was used as a 




















Figure 3.29 Reduced expression of viral capsid protein in cells stably-transfected with 
pshCapsid at both 12- and 24 h p. i. Cell lysates harvested from pshCapsid stably-
transfected and WNV-infected cells show a 8- and 12-folds reduction in viral capsid 
protein production at 12- and 24 h p. i., respectively when compared to wild-type WNV 
infection. Cells transfected with control plasmid pshCapsidscrambled and infected with 
WNV show insignificant differences in capsid production from the wild-type WNV-
infected cells at the two time points. Actin is used as a loading control to ensure equal 







Similar observations were recorded in cells stably-transfected with pshNS2B and 
infected with WNV (Figure 3.30). Cell lysate harvested from this group of cells had 4- 
and 6-fold reductions in the amount of NS2B protein expressed when compared to non-
transfected WNV-infected cells at 12- and 24 h p. i., respectively. This corroborated with 
the number of viral transcripts produced and immunofluorescence results where shRNAs 
produced from the vector was capable of producing a persistent silencing effect on WNV 
replication. 
There was no difference in the production of viral NS2B proteins between the 
cells stably-transfected with pshNS2Bscrambled construct and non-transfected 
counterpart upon infection with WNV. As shown in Figure 3.30, the difference in the 
expression of NS2B proteins was less than 10 % different between the two groups of 
cells at both 12- and 24 h p. i.  This concurred with the fact that silencing of virus using 
RNAi pathway is sequence specific. Cell lysate collected from mock-infected-pshNS2B 
stably-transfected cells which acted as negative control showed no band at both time 
points. The actin was used to act as a loading control to ensure equal amounts of proteins 

























Figure 3.30 Diminished expression of viral NS2B protein in cells stably-transfected with 
pshNS2B at both 12- and 24 h p. i. Cell lysates harvested from pshNS2B stably-
transfected and WNV-infected cells, when compared to non-transfected WNV infected 
cells, reveal 4- and 6-folds reductions in viral NS2B protein synthesis at 12- and 24 h p. 
i., respectively. Cells stably-transfected with pshNS2Bscrambled and infected with WNV 
show no significant differences in NS2B protein production from the wild-type WNV-
infected cells at the two time points. Negative control cell lysate harvested from mock-
infected pshNS2B transfected cell show no expression of viral proteins. Actin was used 






In Figure 3.31, the intensity of the NS4B protein bands were measured. Cell line 
created from transfection of pshNS4B displayed a drastic decrease in the synthesis of 
NS4B protein at 12 h p. i. There was a 4-folds difference in protein level when compared 
to non-transfected WNV-infected cells. However the amount of NS4B proteins harvested 
from cells stably-transfected with pshNS4B increased at 24 h p. i. with almost no 
difference in NS4B protein expression when compared to wild-type WNV-infected cells. 
This affirmed earlier findings that pshNS4B construct was not able to prolong the 
silencing effect on WNV replication.  
Cells stably-transfected with pshNS4scrambled construct and infected with WNV 
showed only approximately 0.20- and 0.10-folds difference in NS4B protein expression 
when measured against the non-transfected WNV-infected counterparts at 12- and 24 h p. 
i., correspondingly. Cell lysate collected from mock-infected-pshNS4B stably-transfected 
cells which acted as negative control showed no band at both time points. The actin was 




























Figure 3.31 Increasing amount viral NS4B protein production in pshNS4B stably-
transfected cells from 12- to 24 h p. i. Cell lysates harvested from pshNS4B stably-
transfected and WNV-infected cells reveal a 4-fold reduction in NS4B protein production 
at 12 h p. i. when compared to non-transfected counterparts. There is no difference in 
viral NS4B protein synthesis between the pshNS4B stably-transfected cells and the non-
transfected cells at 24 h p. i. Cell stably-transfected with pshNS4Bscrambled and infected 
with WNV express similar amount of NS4B protein as the wild-type WNV-infected cells 
at the same time points. Negative control cell lysate harvested from mock-infected 
pshNS4B transfected cell yield no viral NS4B protein. Actin is used as a loading control 





Cells stably-transfected with pshNS5 and infected with WNV were not able to 
inhibit NS5 protein synthesis as indicated in Figure 3.32. There were only 0.25- and 0.40-
fold reductions in the amount of NS5 protein expressed when compared to non-
transfected WNV-infected cells at 12- and 24 h p. i., respectively. This substantiated the 
data collected from real-time PCR and immunofluorescence results (Section 3.17 and 
3.18) where shRNAs produced from the vector was intrinsically unable to inhibit WNV 
replication. 
As expected, the amount of viral NS5 proteins produced from cells stably-
transfected with pshNS5scrambled and infected with WNV were similar to that of the 
non-transfected counterpart infected with WNV. The difference in the expression of NS5 
proteins was less than 0.1-fold different between the two groups of cells at both 12- and 
24 h p. i.  Cell lysate collected from mock-infected-pshNS5 stably transfected cells which 
acted as negative control showed no band at both time points. As previously described, 
actin was used to act as a loading control to ensure equal amount of proteins were loaded 





























Figure 3.32 Lack of inhibition of viral NS5 protein production in cells stably-transfected 
with pshNS5 at both 12- and 24 h p. i.  Cell lysates harvested from pshNS5 stably-
transfected and WNV-infected cells, when compared to non-transfected WNV infected 
cells, show no significant difference in the level of NS5 protein production at both 12- 
and 24 h p. i. Cells stably-transfected with pshNS5scrambled and infected with WNV 
show no significant differences in NS5 protein production from the wild-type WNV-
infected cells at the two time points. Negative control cell lysate harvested from mock-
infected pshNS5-transfected cell shows no expression of viral proteins. Actin is used as a 






3.20 PLAQUE ASSAY TO ASSESS THE PRODUCTION OF INFECTIOUS 
VIRUS PARTICELS  
Cell lines stably-transfected with various vector constructs were tested for their 
ability to limit infectious virus production. The supernatants from the stably-transfected 
and infected tissue cultures (Section 2.2.4) were used for plaque assays to determine the 
virus titre.  
From the reduction in the amount of viral RNA detected and low viral protein 
expression, it was likely that the productivity of progeny virus in cells stably-transfected 
with pshCapsid will be affected. Indeed, there were 3.27- and 3.67 log10 unit decreased in 
the number of virus produced at 12- and 24 h p. i., correspondingly (Figure 3.33). The 
average of the log10 virus particles produced between the two groups of cells were found 
to be significantly different as indicated by the T-test giving P-values of 0.006 and 0.001 
(both p < 0.05) at the two time points.     
Cells stably-transfected with pshCapsidscrambled did not appear to interfere with 
WNV replication. There were a mere 0.08- and 0.11 log10 unit difference in virus 
production when compared to non-transfected WNV-infected cell at 12- and 24 h p. i., 
respectively. The T-tests gave P-values of 0.89 and 0.82 (both P > 0.05) illustrated the 
lack of evidence that mean log10 unit of virus titre was different between the two groups 
of cells.       
Similarly cells stably-transfected with pshNS2B showed reduced level of viral 
RNA transcripts and protein expression, and were expected to interfere with infectious 
virus production.  These cells showed 2.23- and 2.40 log10 unit reductions in the number 
of virus particles produced when compared to wild-type WNV infection at 12- and 24 h 
p. i., respectively (Figure 3.33). The average log10 unit of virus particles produced by 
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these two groups of cells were found to be significantly different as stated by the T-tests. 
The P-values were given to be 0.024 and 0.011 for 12- and 24 h p. i., correspondingly.  
 As expected, there was no indication that pshNS2Bscrambled vector inhibited 
WNV production. Cells stably-transfected with pshNS2Bscrambled showed 0.11- and 
0.08 log10 unit difference in the number of virus particles produced when compared to 
wild-type WNV infection at 12- and 24 h p. i., respectively. T-tests which gave P-values 
of 0.86 and 0.90 (P > 0.05) suggested that the average log10 unit virus particles produced 
by these two groups of cells were not significantly different.   
Likewise, cells stably-transfected with pshNS4B were tested for the production of 
infectious virus particles. As seen from real-time PCR and protein expression analysis, 
these cells were not likely to sustain an inhibition in virus production. These cells showed 
1.23- and 0.49 log10 unit decrease in the number of virus particles produced when 
compared to wild-type WNV infection at 12- and 24 h p. i., respectively (Figure 3.33). 
The mean of log10 unit virus production between pshNS4B-transfected and non-
transfected cells was found to be significantly different at 12 h p. i. (P = 0.033) but not at 
24 h p. i. (P = 0.693). 
The shRNAs generated from pshNS4Bscrambled control vector did not hinder 
virus productivity at both 12- and 24 h p. i. The average log10 unit virus titre of 
pshNS4Bscrambled stably-transfected cells and non-transfected counterpart were 
reported to be similar with only 0.02- and 0.15 log10 unit difference between them at 12- 
and 24 h p. i., respectively. T-tests which gave P-values of 0.86 and 0.91 (both P > 0.05) 
confirmed this set of data.  
As supported by data from real-time PCR and proteomic analysis, cells stably-
transfected with pshNS5 were not able to inhibit progeny virus production. These cells 
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had 1.11- and 0.67 log10 unit decrease in the number of virus produced at 12- and 24 h p. 
i., correspondingly when compared to non-transfected wild-type WNV infections (Figure 
3.33). There was no evidence to suggest that average log10 unit virus produced between 
these two groups of cells was different (P = 0.44 at 12 h p. i., P = 0.25 at 2 h p. i.). 
Similarly, cells stably-transfected with pshNS5scrambled did not show reduction 
in virus titer when compared to non-transfected WNVinfected cells. There were only 
0.28- and 0.14 log10 unit differences in virus production between the two groups of cells 
at 12- and 24 h p. i., respectively. The T-tests gave P-values of 0.83 and 0.85 (both P > 
0.05) illustrated the lack of evidence that mean log10 unit of virus titre was different for 




























































12 h p. i.                              24 h p. i.  
Figure 3.33 Plaque assay revealing the log10 unit inhibition of virus particles production 
in various vectors-transfected cells. Both pshCapsid and pshNS2B stably-transfected cells 
display significantly lower yield of virus particles at both 12- and 24 h p. i. Cells stably-
transfected with pshNS4B showed some inhibition in the number of virus progeny 
produced at 12 h p. i. but not at 24 h p. i. Cells stably-transfected with pshNS5 did not 












3.21 TRANSMISSION ELECTRON MICROSCOPY TO ASSESS THE 
MORHPHOLOGY OF VECTORS-TRANSFECTED CELLS  
In order to give a more complete picture of the effect of RNAi on WNV 
replication, it was necessary to look at the morphology of the transfected and WNV-
infected cells as well as to detect the presence of virus particles. Therefore the cells were 
viewed under the transmission electron microscopy and 100 cells were screened for signs 
of infections in the WNV-infected samples. About 75 % of the non-transfected wild-type 
infected cells appeared to be infected with WNV and numerous virus particles (arrows) 
were observed budding at the cell surfaces after 12 h of infection (Figure 3.34). Similar 
observations with high percentage of cells showing cytopathic effects were recorded for 
non-transfected cells that were infected with WNV at 24 h p. i.      
Vero cells stably-transfected with pshCapsid were protected against WNV 
infection as there was a low infection rate with less than 10 % of the cells showing signs 
of infection (integrity of cells compromised) at both 12- and 24 h p. i. However, no virus 
particle was found from screening of 100 cells. Most of the cells appeared to be healthy 
with numerous mitochondria. In addition, extensive ER proliferation (white arrowheads) 
was a prominent feature in the cytoplasm of the transfected cells (Figure 3.35a).  
Similar to the non-transfected WNV-infected counterparts, Vero cells stably-
transfected with pshCapsidscrambled were infected in high number. Numerous WNV 
particles (arrows) budding out at cell surfaces at the two time points (Figure 3.19b). This 















Figure 3.34 TEM micrograph of non-transfected Vero cells infected with WNV. Virus 























WNV replication. Likewise, pshCapsidscrambled-transfected cells had large amount of 
ER proliferation in the cytosol (data not shown). Vero cells stably-transfected with 
pshCapsid and mock-infected acted as negative control (Figure 3.19c). They displayed 
normal cell morphology with numerous mitochondria. On top of that these cells also had 
large amount of ER proliferation (white arrowheads) within the cells.  
Consistent with the previous findings (Section 3.17  3.20), cells stably-
transfected with pshNS2B were able to silence WNV replication. These cells showed 
similar infection pattern to those stably-transfected with pshCapsid. There was slightly 
less than 10 % of the population having cytopathic effects at both 12- and 24 h p. i. Most 
of the cells appeared healthy and only a few cells out of the hundred cells screened 
showed virus (arrows) budding at the cell surface membranes (Figure 3.36a). Like the 
other transfected cells, ER proliferation was a prominent feature in cells stably-
transfected with pshNS2B.   
Cells stably-transfected with pshNS2Bscrambled and infected with WNV 
exhibited high percentage of infection. More than 80 % of the cells presented with signs 
of infections after 24 h of infection. Numerous virus particles (arrow) were budding out 
at cell surfaces even at 12 h p. i. (Figure 3.36b). Similarly, these cells also had extensive 
ER proliferation in the cytosol (data not shown). Vero cells transfected with pshNS2B 
and mock-infected acted as negative control (Figure 3.36c). These cells had large amount 
of ER proliferation (white arrowheads) in the cytosol otherwise, displaying normal cell 
morphology.  
 
Figure 3.35 TEM micrographs of stably-transfected cells (a): Large amount of ER 
proliferation (white arrowheads) in the pshCapsid stably-transfected and WNV-infected 
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cells at 24 h p. i.; (b): Cells stably-transfected with pshCapsidscrambled are infected by 
WNV with virus (arrows) budding are observed from cell surface after 24 h of infection; 
(c): Vero cells stably-transfected with pshCapsid and mock-infected acting as negative 
control showing ER proliferations (white arrowheads) No virus is seen. The bar 




































































Figure 3.36 TEM micrographs of stably-transfected cells (a): Only a few out of one 
hundred of pshNS2B stably-transfected and WNV-infected cells show virus budding 
(arrows) at 24 h p. i.; (b): Cells transfected with pshNS2Bscrambled are infected in large 
numbers by WNV. Numerous virus particles (arrow) are seen budding from cell surface 
after 12 h of infection; (c): Vero cells transfected with pshNS2B and mock-infected 
acting as negative control showing extensive ER proliferations (white arrowheads). The 
























































It was apparent that cells stably-transfected with pshNS4B did not produce more 
effective silencing when compared to the cells transiently-transfected with the same 
vector. Showing similar trends under the TEM from 12- to 24 h p. i., the number of 
infected cells increased from 41 % to 80 %. As illustrated in Figure 3.37a, progeny virus 
particles (arrows) were budding from these cells. High ER proliferation was observed in 
the cytoplasm of this group of cells (date not shown). 
Vero cells stably-transfected with vector control pshNS4Bscrambled and infected 
with WNV were similar to non-transfected counterparts and had numerous virus particles 
budding out at cell surfaces at the 12- and 24 h p. i. (Figure 3.37b). These cells had 
extensive ER proliferation (white arrowheads) in the cytosol just like the other 
transfected cells. Vero cells transfected with pshNS4B and mock-infected acted as 
negative control (Figure 3.37c). They displayed normal cell morphology with numerous 













Figure 3.37 TEM micrographs of stably-transfected cells (a): Eighty % of pshNS4B 
stably-transfected and WNV-infected cells show signs of infections at 24 h p. i. with 
virus budding (arrows) at the cell surfaces; (b): Cells stably-transfected with 
pshNS4Bscrambled are vastly infected by WNV with numerous virus particles (arrows) 
budding from cell surface after 24 h of infection. ER proliferations within the cells are 
illustrated by white arrowheads; (c): Vero cells stably-transfected with pshNS4B and 
mock-infected act as negative control. ER proliferations in the cytoplasm are indicated by 














































Lastly, cells stably-transfected with pshNS5 and infected with WNV were viewed 
under the TEM to observe the morphology as well as the presence of virus. 
Approximately 45 % of these cells presented with cytopathic effects after 12 h of 
infections. The number of infected cells increased significantly to 80 % with numerous 
virus particles (arrows) budding from the cell surfaces when the infection was allowed to 
go on for 24 h (Figure 3.38a). These observations correlated well to previous experiments 
(Section 3.17  3.20) where cells stably-transfected with pshNS5 was unable to block 
virus replication.    
Cells stably-transfected with pshNS5scrambled and infected with WNV showed 
similar infection patterns to that of non-transfected WNV-infected counterparts. As 
before, progeny virus particles (arrows) were budding from the cell surfaces at both 12- 
and 24 h p. i. (Figure 3.38b).  Cells stably-transfected with pshNS5 and mock-infected 
had normal cell morphology with numerous mitochondria (Figure 3.38c). Similar to the 
other transfected cells, they had extensive ER proliferations (white arrowheads).  
In this study, cells transfected with the various vectors were assessed for their 
ability to disrupt WNV replication. The plaque assay results of the transient transfection 









Figure 3.38 TEM micrographs of stably-transfected cells (a): Cells stably-transfected 
with pshNS5 show high proportion of the cells infected with WNV at 24 h p. i. Numerous 
virus are budding (arrows) at the cell surfaces; (b): Cells stably-transfected with 
pshNS5scrambled are vastly infected by WNV with numerous virus particles (arrows) 
budding from cell surface after 24 h of infection. ER proliferations within the cells are 
illustrated by white arrowhead; (c): Vero cells stably-transfected with pshNS5 and mock-
infected act as negative control. ER proliferations in the cytoplasm are indicated by white 















































































































































































































































































































































































































































































































































































































































































































































































































































































RNA interference is a sequence specific post-transcriptional gene silencing 
process triggered by the presence of dsRNAs. The activated RNAi pathway produced 
selective silencing effects through generation of siRNAs that lead to the degradation of 
homologous mRNA in the cytoplasm. The development of RNAi technology has allowed 
the control of specific gene expression, hence elucidating the role of the gene. This has 
been of great importance in understanding viral invasion and its underlying molecular 
interactions. This not only acts as a platform for fundamental research into the 
pathogenesis of mammalian viruses but also permits the uncovering of novel therapeutic 
targets. The siRNA construct itself may be developed as a novel antiviral agent to combat 
viral infection and disease. 
Using RNAi as an anti-WNV tool presented certain important advantages. By 
specifically targeting viral transcripts and proteins, its replication process could be 
severely impaired and this promotes eradication without seemingly activating non-
specific cellular responses. In addition, the numerous potential targets for siRNA along 
the viral genome make it possible to target conserved and multiple regions limiting the 
evolution of escape mutants. The capacity to introduce several different sequences 
expands the potentiality to treat viral diseases from related numbers of the same virus 
family such as WNV, dengue virus and Hepatitis C virus. 
Recent studies have reported disruption to WNV replication via RNAi. Deas and 
co-workers (2005) made use of phosphorodiamidate morpholino antisense oligomers to 
target the untranslational regions (UTRs) of the WNV. In addition, an Arginine-rich 
peptide was conjugated to each oligomer to enhance delivery to the cultured cells. Bai 
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and coworkers (2005) demonstrated injection of chemically synthesized siRNAs into  
mice reduced viral load and offered some protection against lethal WNV encephalitis. 
Although chemically synthesized siRNAs that were transfected into cells had been shown 
to be functional in silencing targeted genes, the problems of non-specific shut-down of 
protein synthesis, activation of interferon response, low transfection efficiency, high cost 
and transient effects exerted by siRNA still exist (Bass, 2001; Robbins and Rossi, 2005). 
Hence to overcome some of these problems, vector-based expression systems where 
RNA polymerase (pol III) promoters are incorporated to drive the synthesis of short 
RNAs in the cells, was developed (Brummelkamp et al., 2002). 
Small interfering RNAs can be produced in the cells either by generating and 
annealing two separate strands of RNA or formation of shRNA which subsequently get 
processed by Dicer. The latter is a more preferred method as it shows greater efficacy in 
silencing activity (Miyagishi and Taira, 2002). Both viral and plasmid vectors have been 
utilized to produce shRNAs. Viral vectors have been employed mainly because of its 
high transduction efficiency. In 2006, Kumar and colleagues demonstrated the use of 
lentiviruses to produce shRNA that protected some mice from fatal encephalitis induced 
by the flaviviruses, WNV and JEV. Other viral vectors available in the market to 
transduce shRNA sequences into the cells include the retrovirus and adenovirus. 
However, the uses of these viral vectors pose some risks such as insertional mutagenesis 
and patients may become infected with the vector viruses. The presence of different 
strains of virus in the host may also result in mutation of nucleic acids and formation 
replication competent virus (Yin and Hu, 1997). In addition, there may be activation of 
immune response (Muruve, 2004).   
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Expression plasmids allow the continuous production of shRNAs in the cells 
which enable sustained silencing of the target genes. There are several expression 
plasmids available in the market which allows cloning of annealed oligonucleotides into 
the plasmids. These plasmids are then transfected into the cells. The duration for 
expression of siRNAs can be controlled with the introduction of inducible plasmids such 
as one containing the tetracycline operon. The expression of siRNA can also be 
constitutive with the use of Pol III or CMV promoter. McCown et al. (2003) transfected a 
plasmid, that expressed shRNAs constitutively under the RNA I polymerase promoter 
into cultured cells. It was shown to reduce the productivity of WNV by targeting WNV 
Capsid and NS5 genes. Similarly, Geiss and colleagues (2005) transfected the shRNAs, 
that was expressed in vitro into cultured cells to disrupt WNV replication. However, in 
these studies, the plasmids did not allow selection and maintenance of the plasmid in the 
transfected the cells as they lacked selectable markers. Therefore, these plasmids may be 
lost from the cells after few passages.  
In this project, the pSilencer vector was employed to allow continuous production 
of shRNAs in cells as the vector backbone contains a selectable marker. This allows the 
option of selecting positively-transfected cells and creating a stable cell line. There has 
been no reported study carried out on pSilencer stably-transfected cell line.  
The other advantages of this system include the absence of cytotoxicity induced 
by the presence of plasmid in the transfected cells (Figures 3.2, 3.9 and 3.23) and the lack 
of interferon pathway activation (Zhang et al., 2004), which is a concern when using 
chemically synthesized siRNA or viral vectors as it may mask the silencing effects. 
Moreover, Vero cells used in this study do not produce interferon (Stanwick and Hallum, 
1974), hence eliminating the non-specific translational arrest in the cells (de Veer et al., 
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2005). The oligonucleotides were designed to include 21-nt of the target sequence. The 
shRNAs stems are shorter than 29 base pairs and have no known immunostimulatory 
RNA motifs (Judge et al., 2005; Hornung et al., 2005) to induce interferon response in 
the host. In addition, five thymidine residues are incorporated into the design of shRNAs 
to allow transcriptional termination by the RNA polymerase. The shRNAs also have a 2 
nt 3 overhang, a feature required by the Dicer (Yi et al., 2003).  
RNA interference works by complementary base pairing between the siRNA and 
target mRNA and subsequent degradation of the entire mRNA. The NS5 protein, which 
functions as a methyltransferase and RNA-dependent RNA polymerase, was selected as a 
target site for destruction. This is because in the event of incomplete destruction of 
mRNA, partial degradation of the NS5 gene site will still render the virus inactive in 
replication. Ideally the target mRNA site should be within a more conserved region with 
a relatively high homology within the flaviviridae family (Coia et al., 1998). This will 
discount the potential for loss of homology due to genetic mutation and strain variation. 
However, siRNA Target Finder software supported by the Ambion website did not 
compute any potential target site within the conserved region thus implying that the 
sequence of the conserved region did not match the selection criteria decided by the 
algorithm. The pshNS5-1 construct could not be used to silence other flavivirus target 
site. Nevertheless, the vector can be used to silence other WNV strains as the target site is 
conserved among several strains.   
In this study, the cells were initially transfected transiently with the vector to 
determine effectiveness of shRNA generated from the plasmid in silencing WNV 
replication before creating a stable cell line as this can be a lengthy and tedious process. 
It was demonstrated that the plasmid construct pshNS5-1 was able to disrupt WNV 
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replication as indicated by the reduction in viral transcripts (Figure 3.3) and protein 
expression (Figures 3.4g, 3.4h and 3.5). This was confirmed by a decrease in the number 
of infectious virus particles produced when compared to the non-transfected WNV-
infected cells (Figures 3.6 and 3.7b). Although there are few criteria available for 
designing siRNA, the precise mechanism of how the siRNA work against its target is still 
unknown. It was therefore necessary to design several siRNAs against different target 
sites on the WNV genome before choosing the best knock-down site (Kumar et al., 2003; 
Hsieh et al., 2004). Previous attempts to interfere with WNV replication targeted the viral 
UTRs, E protein, Capsid and NS5 sites (Deas et al., 2005; Bai et al., 2005; Kumar et al., 
2006; McCown et al., 2003; Geiss et al., 2005)). Other target sites on the WNV genome 
have not been studied. In this study, the different sites of the genome Capsid, NS2B and 
NS4B were targeted to compare the efficacies of the different shRNAs in reducing WNV 
production. Although the siRNA WNV CAP (McCown et al., 2003) and pshCapsid 
targeted the same region of the viral genome, it was still worth studying the effects of 
targeting at a shorter region of the Capsid gene using the plasmid based vector.  
The siRNAs generated from pshCapsid and pshNS2B were more effective in 
interfering with WNV replication as the amount of WNV transcripts reduced by at least 2 
log10 units greater (Figure 3.10) compared to cells transfected with pshNS5-1. This was 
translated to larger reductions in viral protein expressions (Figures 3.14 and 3.15). 
Confirming these observations, cells transfected with pshCapsid and pshNS2B also 
showed 1 log10 unit greater decrease in virus titer than cells transfected with pshNS5-1 
(Table 3.1). However, cells transfected with pshNS4B were not as efficient as the cells 
transfected with pshCapsid and pshNS2B in disrupting WNV replication. These cells 
were unable to sustain the silencing effect. Virus was replicating actively in these cells 
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(almost similar to that of the non-transfected WNV-infected cells) after 24 h of infections 
(Figures 3.13h and 3.16). This was different from the cells transfected with the other 
shRNAs. Although, there was a decrease in the inhibition power of the pshNS5-1 cells, 
the difference between the transfected cells and non-transfected cells was still significant 
(Table 3.1).   
Cultures transiently-transfected with various vectors (pshNS5-1, pshCapsid, 
pshNS2B and pshNS4B) showed different degree of ability to silence WNV replication. 
However, there was no complete inhibition of virus production. The observation is not an 
uncommon observation in oligonucleotide-based expression systems (Tuschl, 2002). 
Consideration should be given to the possibility that different cell types vary in their 
response to the introduction of siRNA vectors (Koromilas, et al., 2001). Some 
postulations could explain this incomplete silencing of virus replication. Firstly, since 
transfection efficiency was usually less than 100%, the increase in number of fluorescing 
cells over time may be infected cells (accumulating virus proteins / progeny virus) 
without the vector constructs. The transfection efficiency was indeed only approximately 
50% in Vero cells in the experiments performed.  The increase in WNV positively-
infected cells could also be due to the infection of previously non-infected cells by the 
progeny virus in the second cycle of infection. Secondly, even though the target site for 
the siRNA was selected using a computer program based on certain criteria, the siRNAs 
may have an intrinsic inability to sustain the silencing effect. This could be due to site 
inaccessibility as a result of secondary structures or presence of other interacting proteins 
which the computer program did not factor in during the selection. Thirdly, the vector 
constructs may be unstable over time thus, resulting in the increase in the titre of virus 
particles after 24 h of infections.  
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 To determine if the lack of complete inhibition on virus replication was due to 
the non-homogenous population of transfected cells, the next phase of the project was to 
use antibiotic G148 to select positively-transfected cells. These cells in turn will express 
shRNAs constitutively under the H1 promoter.  
Similar to the transient study, the stably-transfected cells were infected with 
WNV and analyzed for the amount of viral transcripts, protein expressions and virus 
production. A more homogenous population of the stably-transfected cells was expected 
to give a better silencing effect than the transiently-transfected counterparts. Surprisingly, 
there was no enhanced down-regulation of WNV genome transcripts and viral protein 
expression in the pshCapsid, pshNS2B and pshNS4B stably-transfected cells when 
compared to the transiently-transfected cells (Figures 3.24, 3.29 and 3.30). Therefore, the 
inhibition of virus production was then expected to be of no difference to the transiently-
transfected cells. Indeed, both pshNS2B and pshNS4B stably-transfected cells did not 
show greater log10 unit reduction in virus titer (Tables 3.1 and 3.2). The pshNS2B was 
able to reduce viral load by about 2 log10 unit while pshNS4B could not sustain the 
silencing effect. Interestingly, cells stably-transfected with pshCapsid showed a further 
increase of 1 log10 unit reduction in virus production when compared to the 
corresponding transiently-transfected cells (Tables 3.1 and 3.2). This indicated that 
pshCapsid is most effective in reducing viral load when compared to the other three 
vectors.  
A distinctive difference was observed between the pshNS5 stably-transfected 
cells and the pshNS5-1 transiently-transfected cells. The stably-transfected group did not 
show any significant difference in the amount of viral transcripts (Figure 3.24), viral 
protein expressions (Figures 3.28g, 3.28h and 3.32) and progeny virus produced (Table 
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3.2) when compared to the non-transfected WNV-infected cells. This could imply that the 
siRNAs generated from pshNS5 could not sustain the induction of viral genome 
destruction. This was different from the pshNS5-1 transiently-transfected cells where the 
log10 unit reduction in virus particles was significant [(even though there was only 1 and 
0.4 log10 unit difference at both time points) (Table 3.1)].  
The reason for the inability of the pshNS5 stably-transfected cells to silent WNV 
replication could be due to mutations. As RNAi works by a sequence specific degradation 
of target, any mismatch resulted from a change in the sequence of the target or siRNA 
produced will render the pathway ineffective. RNA virus has been known to be prone to 
mutation when it infect and replicate in the cells. The RNA dependent RNA polymerase 
(RdRp) without the proofreading mechanism can introduce mutation to the viral genome 
(Zheng et al., 2005). Hence, there may be a mutation in the viral NS5 target sequence 
which the siRNA produced from the pshNS5 vector is unable to bind to the target site. 
The positively pshNS5-transfected cells were passaged through several rounds to 
allow the creation of a stable cell line which constitutively express shRNA. Therefore it 
may not be surprising that mutation could occur in the pshNS5 vector carried by these 
transfected cells which in turn resulted in the production of shRNAs with a change in the 
sequence. Hence, the mismatch in the sequence between the target sequence and the 
siRNA resulted in non-degradation of the viral genome when the virus entered into the 
transfected cells.  
It was observed that different vectors produced varying silencing effect on WNV 
replication. There have been reports stating that the efficiency of silencing of the target 
gene is dependent on both the design of the siRNA (as described above) and the 
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secondary structure of the target RNA. There is an inverse relationship between the 
stability of the secondary structure of the target region and the silencing activity. Highly 
structured target region where the nucleotides are involved in the base pairing or 
formation of hairpin structure may hinder the ability of the RISC to bind to it, hence 
disallowing its degradation initiated by the RISC (Schubert et al., 2005).   
To shed some light on the lower potency of siRNA generated by pshNS5-1 
against WNV, the various target sites were analyzed using RNA secondary structure 
prediction program Mfold (hosted at 
http://www.bioinfo.rpi.edu/applications/mfold/rna/form1.cgi). As Mfold computes 
multiple RNA secondary structures for each gene target, the most common secondary 
structure predicted was taken to be the most likely secondary structure for our target 
gene. Using this program, a common trend was observed. The greater the number of 
nucleotides of the target sites involved in base pairing, the less effective silencing of 





The Mfold program predicted that the nucleotides of pshCapsid vector target site had the 
least number of base pairing with no formation of hairpin structure (Figure 4.1a). This 
may account for the highest potency in silencing WNV replication among the 4 target 
sites as the activated RISC may be able to attack the site more easily. The nucleotides of 
pshNS2B target has slightly more base pairing than that of pshCapsid target site 
hence, may account for the slight reduced in the potency of siRNA generated from 
pshNS2B in the stably-transfected cells (Figure 4.1b). More than 66% of the nucleotides 




Figure 4.1 RNA secondary structure prediction of various siRNA target sites using 
MFold program (a): Secondary structure of pshCapsid target site (highlighted in green); 
(b): Secondary structure of pshNS2B target site (highlighted in green); (c): Secondary 
structure of pshNS4B target site (highlighted in green); (d): Secondary structure of 
pshNS5-1 (pshNS5) target site (highlighted in green) 
pshNS4B target site are involved in pairing its complementary bases which resulted in 
the bases which resulted in the formation of a stem (Figure 4.1c). The remainder of the 
target sequence is made up of a continuous stretch of unpaired nucleotides located in 
between stem structures hence this may have still allowed the RISC to bind and initiate 
the degradation of the RNA genome. However, the destruction of the viral genome is not 
optimal due to the presence of secondary stem structure causing silencing efficiency to be 
reduced with no sustainable WNV silencing in pshNS4B-transfected cells after 24 h of 
infection. Next, the secondary structure of pshNS5 (pshNS5-1) target site was predicted 
in Figure 4.1d. Compared to the pshNS4B target site, the siRNA target site of the pshNS5 
vector not only has high number (66 %) of nucleotides involving in base pairing, the 
unpaired nucleotides are not clustered together to form a continuous stretch. This may 
hinder the proper binding of RISC to the target site hence, showing the poorest silencing 
efficiency among the four vectors.    
Even though shRNA generated from pshCapsid vector gave the highest viral 
silencing power, there was no complete inhibition of virus replication. Similar 
observations were recorded for the other three (pshNS2B. pshNS4B and pshNS5) stably-
transfected cell lines. Geiss and colleagues (2005) had suggested that the flaviviruses like 
WNV replicate in cellular compartments protected by the virus-induced membranes. 
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Thus, may disallow the RISC complex in the cytosol to reach the target viral genome, 
hence resulting in RNAi resistance which is consistent with our data.  
Although WNV is able to partially resist RNAi resulting in the lack of complete 
inhibition of virus replication, studies had shown the siRNAs is still able to offer 
protection against complications arising from WNV infections in the animal models. The 
mice had reduced viral load and were protected from lethal encephalitis when the siRNAs 
were administered by hydrodynamic injection into the circulatory system or directly into 
the brain (Bai et al., 2005; Kumar et al., 2006). Hence, our constructs (pshCapsid and 
pshNS2B) may also offer protection against WNV induced complications in the animals 
and this may be further developed for application to humans. 
Being a dynamic process, it is possible that siRNA may cause imbalance within 
normal cellular biochemical processes and regulatory systems. However, morphological 
studies (Sections 3.7, 3.14 and 3.21) suggested that gene silencing did not induce obvious 
side effects. The vector-transfected and mock-infected cells appeared healthy with cell 
integrity intact. The silencing process was found to consumed high levels of cellular 
ATPs (Nykanen et al., 2001), and this coincided with the large number of mitochondria 
seen. 
In addition, extensive endoplasmic reticulum (ER) was observed in the 
transfected cells under the TEM. It has been reported that RISC is closely associated with 
the polyribosomes in the cytosol and most siRNA can be extracted from the complexes, 
implying an interaction between translation and RNAi machinery (Hammond et al., 2000, 
Djikeng et al., 2003). The continuous expression of siRNA in transfected Vero cells may 
interact with the intracellular RISC and associate with the ribosomes on the ER. This may 
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in turn affect the ER dynamic, leading to the biogenesis of the ER. In addition, extensive 
ER expansion did not appear to affect normal physiology of the cells and the process is 
reversible (Federovitch et al., 2005). Therefore, siRNA inhibition of flavivirus infections 
could be an attractive therapeutic tool. The ultrastructural study correlates with the study 
done by Jiang and Milner (2002) which demonstrated that RNA interference does not 
hinder recovery of endogenous regulatory systems during siRNA-primed silencing of 
viral genes in human cells.  
Despite the massive prospects of siRNA in therapeutic and antiviral treatment, it 
is not a perfect antidote to viral diseases. Short-term assays have suggested that siRNA 
may be a powerful new method for intracellular immunization (Surabhi and Gaynor, 
2002; Xia et al., 2002). However, it has not yet been shown to protect cells in long term 
virus replication assays. The sequence-specific antiviral effect of siRNA can behave like 
a double edge sword, providing a selective pressure for viruses to undergo diverse 
deletions and substitutions (Das et al., 2004).   
Studies done on vaccinia virus, reovirus and human influenza A, B and C viruses 
showed evidence of suppressors of siRNA within the virus genome (Li et al., 2004; 
Zheng et al., 2005). These viruses each encode an essential protein that suppresses host 
RNA silencing-based antiviral response in Drosophila cells. The virus suppressors, E3L, 
σ3 and NS1 produced by vaccinia virus, reovirus and influenza viruses, respectively, are 
distinct double-stranded RNA-binding proteins. In addition, the NS1 protein in the 
influenza virus plays a role in pathogenesis by inhibiting the mammalian IFN-regulated 
innate antiviral response. It may be possible that WNV also encodes a gene of similar 




Although the morphological studies suggested that siRNA does not induce 
adverse effects on cell physiology, the use of siRNA for therapeutics purpose requires 
further investigation. The introduction of exogenous siRNAs might have an impact the 
cellular protein expressions. There may be translation repression of cellular mRNA where 
the sequence motif resembled part of the viral target sequence. Genome-wide expression 
profiling did not reveal such adverse effects on cellular functions (Chi et al., 2003; 
Semizarov et al., 2003) but another finding using oligonucleotide-based system indicated 
cross-silencing of mRNAs with related sequence (Jackson et al., 2003). In this study, the 
target sequences were BLASTed against Genbank databases to ensure no similarity in 
sequence to human/monkey, therefore minimising the chances of cross silencing due to 
complementary homology.  
This study demonstrated the potential of RNAi to inhibit WNV replication, and 
determined the optimal target sites among the different clones. The results also illustrated 
that for effective silencing, one needs to screen the full length of virus genomes for the 
best target site. An obvious gene like the NS5 (polymerase) protein was proven not to be 
as effective as originally anticipated. On the other hand targeting the gene encoding small 
non-structural protein like the NS2B showed almost equal silencing as the gene of the 
structural capsid protein.  
 Further study can be done to investigate the effect of combining different 
plasmids (pshCapsid and pshNS2B) which target at different sites of the WNV (Sarafend) 
viral genome to prevent escape mutants. In addition, these two constructs can be used to 
silence different strains of WNV as the target sites are conserved among the various 
strains. A suitable animal model should be developed to investigate the suitability of such 
plasmids combination model for in vivo study.  
Discussion 
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However, the major obstacle in RNAi is still the delivery of plasmids to the 
desired destination. Many groups had successfully administered the liposome-nucleic 
acid complexes or lentiviral system to the animals via hydrodynamic injection or 
intracranial injection. Nevertheless, these methods are not applicable to humans. More 
studies are required to develop with better delivery systems where the DNA vector can be 
distributed to its designated cells. If specific delivery systems are developed, RNAi 
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APPENDIX 1: MEDIA FOR TISSUE CULTURE 
a) M199 Medium (10 % FCS): Growth medium for Vero Cells 
 
Items      Amount  Source 
M199 Powder     11.0g  Sigma, USA 
Foetal calf serum    100ml  Biological Industries,Israel  
(Inactivated at 56oC for 30 min) 
NaHCO3     2.2g  Merck, Germany 
1 bottle of M199 medium powder was dissolved in 900 ml of nanopure water (Barnstead, 
USA). 2.2 g of NaHC03 was then added and the pH adjusted to 7.2. Sterilization was 
carried out by filtration through a 0.22µm filter (Sterivex G-S, Millipore, USA). The 
media was then stored in aliquots at 4°C. FCS was added as required prior to use. 
b) 10 x Phosphate Buffered Saline [(PBS) (pH 7.4)] (per litre) 
Item   Amount Source 
NaCl    80.0 g  Merck, Germany 
KCl    2.0 g  Merck, Germany 
KH2PO4   2.0 g  Merck, Germany  
Na2HPO4   11.5g  Merck, Germany 
To prepare the l0x PBS stock solution, the specified constituents were added to 900 ml of 
nanopure water (Barnstead, USA) and the pH adjusted to 7.4. The solution was top up to 
1 L and then autoclaved at 121°C for 15 min. The stock solution was then stored at room 
temperature. To prepare the working (1 x) PBS, 10x PBS stock solution was diluted 1:10 
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with nanopure water. The solution was then autoclaved at 121°C for 15 min and 
subsequently stored at 40C.  
c) M199 Medium (2 % FCS): Maintenance medium (MEM) for Vero Cells 
Items     Amount Source 
M199 Powder    11.0g  Sigma, USA 
Foetal calf serum   20ml  Biological Industries, Israel  
NaHCO3    2.2g  Merck, Germany 
1 bottle of M199 medium powder was dissolved in 980 ml of nanopure water. 2.2 g of 
NaHC03 was then added and the pH was adjusted to 7.2. Sterilization was carried out by 
filtration through a 0.22µm filter (Sterivex G-S, Millipore, USA). The media was then 
stored in aliquots at 4°C. FCS was added as required prior to use. 
d) Trypsin/Versene (ATV) Solution 
Item   Amount  Source 
NaCl   80.0g   Merck, Germany 
KCl   4.0g   Merck, Germany 
D-glucose  10.0g   Analar, UK 
NaHCO3  5.8g   Merck, Germany 
Trypsin  5.0g   Difco, New Zealand 
Versene(EDTA) 2g   Sigma, USA 
The specified constituents were added to 1000 ml of nanopure water (Barnstead, USA) 
and the mixture was heated to 30°C with occasional shaking (for 3 to 4 hours) to dissolve 
Appendices 
 184
the trypsin. The solution was than filtered through a 0.22µm filter (Sterivex G-S, 
Millipore, USA). Ten millimeters of this solution was added to 90ml of nanopure water 

















APPENDIX 2: MATERIALS FOR PLAQUE ASSAY 
a) Virus Diluent 
 
Item     Amount  Source 
 
Hanks Balanced Salt Solution 11.0 g   Sigma, USA 
 
10% Bovine Serum Albumin  1 ml   CSL, Australia 
 
Sodium Bicarbonate Powder  2.2 g   Merck, Germany  
 
All reagents were dissolved in 100 ml of nanopure water (Barnstead, USA) and pH to 
7.2. The solution was sterilized by filtration through a 0.22 µm filter unit ( Sterivex G-S, 
Millipore, USA). Storage was at 4oC. 
 
b) 2.5% Carboxymethylcellulose (CMC) 
To make 100 ml of 2.5% CMC, 2.5 g of carboxymethylcellulose (Aquacide IL 
Calbiochem, USA) was resuspended in 100 ml of nanopure water. The suspension was 
then autoclaved for 15 min at 121°C and then kept at 4°C. 
 
c) Crystal Violet staining solution 
 
Items     Amount Source 
Crystal Violet     1.85 g  Sigma, USA 
 
37% formaldehyde     270 ml  Merck, Germany 
 





APPENDIX 3: REAGENTS FOR BACTERIA CULTURE  
a) Luria-Bertani (LB) Plate, pH 7.0  
 
Items     Amount Source 
Bacto-tryptone   10g  BD Bioscience, USA 
Bacto-yeast extract   5g  BD Bioscience, USA 
NaCl     10g  Merck, Germany 
Agarose    10g  Oxoid, UK 
Ampicillin (100 mg/ml)  1ml  Sigma, USA 
 
The above components were dissolved in 1.0 liter of deionised water. The solution was 
autoclaved at 121 ºC for 15 min (Hirayama, Japan) and cooled to 60 °C before adding 
antibiotic and pouring plates. Storage was at 4 °C. 
  
b) Luria-Bertani (LB) Broth, pH 7.0  
 
Items     Amount Source 
Bacto-tryptone   10g  BD Bioscience, USA 
Bacto-yeast extract   5g  BD Bioscience, USA 
NaCl     10g  Merck, Germany 
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The above components were dissolved in 1.0 liter of deionised water. The solution was 




















APPENDIX 4: REAGENTS FOR IMMUNOFLUORESCENCE 
a) 10% Bovine Serum Albumin (BSA) 
Ten g of bovine serum albumin power, Fraction V (Gibco BRL) was dissolved in 100 ml 
PBS (Appendix 1b). The solution was then aliquoted and stored at -20° C. To get 1.0% 
BSA, 1ml of 10% BSA was diluted in 10ml PBS (Appendix 1b).  
b) Mountant 
Items       Amount Source 
1 g of 1,4-Diazabicyclo[2.2.2]octane, DABCO  1 g  Sigma, USA   
0.1 M Tris-HCl (pH 7.6)     1 ml  Merck, Germany 
Glycerol       9 ml  Merck, Germany 













APPENDIX 5: MATERIALS FOR SODIUM DOECYL SULPHATE  
POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS PAGE) AND WESTERN 
BLOTTING 
 
a) Dye Mixture (Stock Solution) 
Items       Amount Source 
0.05M Bromophenol Blue    1.0 ml  Sigma, USA 
Glycerol      1.0 ml  Analar, UK 
0.5M Tris Buffer pH 6.8      10.0 ml Merck, Germany 
Cocktail for Samples 
A 1000µl cocktail of dye mixture stock solution were mixed with 100mg of 
dithioerythritol (Biorad, USA). To every 25µl of sample, 5 µl of this cocktail was added. 
After mixing the sample with cocktail, the mixture was boiled for 1 minute in a water 
bath before loading onto the gel.  
 
b) Separation Gel (12% SDS PAGE) 
Items       Amount Source 
30% acrylamide & 0.8% bis acrylamide  12.0 ml Merck, Germany 
0.5M Tris Buffer pH 6.8    11.25 ml Merck, Germany 
10% SDS       0.30 ml Merck, Germany 
Deionised Water     6.35 ml Elga, UK 
TEMED       40.0 µl  Merck, Germany 
10% Ammonium Persulphate    400 µl  Merck, Germany 
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The chemicals were added in the above order 
 
c) Stacking Gel (5% SDS PAGE) 
Items       Amount Source 
30% acrylamide & 0.8% bis acrylamide  1.67 ml Merck, Germany 
0.5M Tris Buffer pH 6.8    2.50 ml Merck, Germany 
10% SDS       0.10 ml Merck, Germany 
Deionised Water     5.70 ml Elga, UK 
TEMED       40.0 µl  Merck, Germany 
10% Ammonium Persulphate    200 µl  Merck, Germany 
The chemicals were added in the above order 
 
d) Upper Tank Running Buffer (pH 8.9) 
Items       Amount Source 
Tris       6.07 g  Merck, Germany 
Glycine      28.73 g Merck, Germany 
SDS         2.0 g   Merck, Germany 
The above was dissolved in 1 litre of deionised water to make a 2X concentrated solution. 
From this concentrated solution, 250ml was diluted to 500ml and used as the top chamber 
buffer.  
 
e) Lower Tank Running Buffer (pH 8.9) 
Items       Amount Source 
Appendices 
 191
Tris       6.07 g  Merck, Germany 
Glycine      28.73 g Merck, Germany 
SDS         2.0 g   Merck, Germany 
The above was dissolved in 1 litre of deionised water to make a 2X concentrated solution. 
From this concentrated solution, 750 ml is diluted to 4 litre. 
 
f) Transfer Buffer 
Items       Amount Source 
Tris (hydroxymethyl)- aminoethane   3.03 g  Merck, Germany 
Glycine      14.40 g Merck, Germany 
Methanol       200.0 ml Merck, Germany 
Deionised Water     800.0 ml Elga, UK 
 
g) 5% Skim Milk Blocking Solution 
Items       Amount Source 
Skim Milk Powder     5.0 g  Dumex, Singapore 







APPENDIX 6: MATERIALS FOR ELECTRON MICROSCOPY 
a) 4 % Glutaraldehye in 1x PBS.  
Items       Amount Source 
Paraformaldehyde Powder     4g  Merck, Germany 
1 x PBS      100 ml   See Appendix 1 b 
 
b) 5 % gelatin 
Items       Amount Source 
0.1 M Sodium Cacodylate Buffer   16.0 ml See Appendix 7 (b) 
5 % Osmium Tetroxide Stock   4.0 ml  TAAB Labs, UK 
Before use, few crystals of potassium ferricyanide (Merck, Germany) were added to the 
solution and mixed thoroughly. The resultant brown solution was then used to fix cells.  
 
c) Saturated Uranyl Acetate Solution 
Items       Amount Source 
Ryter Kellenburger Buffer     5.0 ml  See Appendix 7 (e) 
0.1 M CaCl2      5.0 ml  Merck, Germany 
0.1 M HCl      6.5 ml  Merck, Germany 
Uranyl Acetate     1.25 g  Merck, Germany 
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Deionised Water     13.0 ml Elga, UK 
The saturated solution was stored in a dark bottle at room temperature. 
 
d) Reynolds Lead Citrate Solution 
Items       Amount Source 
Lead Nitrate       1.33 g  BDH, UK 
Sodium Citrate     1.76 g  BDH, UK 
Boiled Deionised Water    30 ml  Elga, UK 
The above components were mixed in a 50 ml volumetric flask and mixed intermittently 
by shaking to ensure complete conversion of lead nitrate to lead citrate. Finally 8 ml of 1 
M NaOH was added and the solution was made up to 50 ml with boiled deionised water. 













APPENDIX 7: LACTOSE DEHYDROGENASE CYTOTOXICITY TEST 
a) Cell transiently-transfectd with pshNS5-1 








0.233 0.157 0.361 0.250 0.102 
Negative control 0.419 0.366 0.192 0.326 0.119 
 
b) Cells transiently-transfected with pshCapsid, pshNS2B and pshNS4B 








0.406 0.136 0.343 0.295 0.141 
Cells transfected 
with pshNS2B 




0.341 0.246 0.327 0.304 0.051 
Cells transfected 
with pshNS4B 
0.306 0.119 0.400 0.275 0.143 





Negative Control 0.419 0.366 0.192 0.325 0.118 
 
C) Cells stably-transfected with pshCapsid, pshNS2B, pshNS4B and pshNS5. 








0.676 0.403 0.353 0.477 0.173 
Cells transfected 
with pshNS2B 




0.338 0.408 0.650 0.465 0.163 
Cells transfected 
with pshNS4B 




0.342 0.423 0.641 0.468 0.154 
Cells transfected 
with pshNS5 




0.404 0.409 0.641 0.484 0.135 
Negative Control 0.313 0.252 0.651 0.405 0.214 
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APPENDIX 8: REAL-TIME PCR (LOG10 UNIT INHIBITION) 
a) Cell transiently-transfectd with pshNS5-1 
 1st Expt 2nd Expt 3rd Expt Average Standard 
Deviation 
Cells transfected with 
pshNS5-1 






Cells transfected with 
pshNS5scrambled-1 
0.306 0.683 0.236 0.408 0.240 
Cells transfected with 
pshNS5-1 






Cells transfected with 
pshNS5scrambled-1 
0.227 0.035 0.954 0.405 0.484 
 
b) Cells transiently-transfected with pshCapsid, pshNS2B and pshNS4B 
 1st Expt 2nd Expt 3rd Expt Average Standard 
Deviation 
Cells transfected with 
pshCapsid 
5.604 3.415 5.639 4.886 1.274. 
Cells transfected with 
pshCapsidscrambled 
0.350 0.175 -0.647 0.040 0.533 
Cells transfected with 
pshNS2B 
7.119 5.140 40177 5.549 1.102 
Cells transfected with 
pshNS2Bscrambled 






Cells transfected with 
pshNS4B 
0.910 1.882 1.618 1.471 0.502 
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 Cells transfected with 
pshNS4Bscrambled 
-0.420 0.411 1.471 0.487 0.947 
Cells transfected with 
pshCapsid 
6.873 5.183 4.519 5.525 1.214 
Cells transfected with 
pshCapsidscrambled 
1.619 0.394 0.402 0.805 0.705 
Cells transfected with 
pshNS2B 
5.288 6.313 2.705 4.769 1.859 
Cells transfected with 
pshNS2Bscrambled 
1.077 0.166 0.420 0.554 0.469 
Cells transfected with 
pshNS4B 






Cells transfected with 
pshNS4Bscrambled 
-0.534 0.849 -0.612 0.099 0.822 
 
C) Cells stably-transfected with pshCapsid, pshNS2B, pshNS4B and pshNS5. 
 1st Expt 2nd Expt 3rd Expt Average Standard 
Deviation 
Cells transfected with 
pshCapsid 
3.835 4.605 3.905 4.115 0.426 
Cells transfected with 
pshCapsidscrambled 
0.096 -0.420 -0.512 -.0288 0.339 
Cells transfected with 
pshNS2B 
3.861 5.166 4.973 4.667 0.704 
Cells transfected with 
pshNS2Bscrambled 






Cells transfected with 
pshNS4B 
3.625 3.957 3.861 3.814 0.171 
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Cells transfected with 
pshNS4Bscrambled 
0.617 -0.612 0.418 0.169 0.683 
Cells transfected with pshNS5 0.831 0.157 0.901 0.630 0.410 
 
Cells transfected with 
pshNS5scrambled 
0.306 0.437 -0.499 0.0817 0.507 
Cells transfected with 
pshCapsid 
3.931 4.413 5.394 4.579 0.745 
Cells transfected with 
pshCapsidscrambled 
-0.586 -0.604 -0.035 -0.408 0.323 
Cells transfected with 
pshNS2B 
4.387 4.500 4.299 4.395 0.323 
Cells transfected with 
pshNS2Bscrambled 
0.096 0.481 0.262 0.280 0.193 
Cells transfected with 
pshNS4B 
1.190 0.691 0.910 0.931 0.250 
Cells transfected with 
pshNS4Bscrambled 
0.341 -0.586 -0.589 -0.271 0.530 






Cells transfected with 
pshNS5scrambled 












APPENDIX 9: PLAQUE ASSAY (LOG10 UNIT INHIBITION) 
a) Cell transiently-transfectd with pshNS5-1 
 1st Expt 2nd Expt 3rd Expt Average Standard 
Deviation 
Cells transfected with 
pshNS5-1 






Cells transfected with 
pshNS5scrambled-1 
-0.029 0.017 -1.091 -0.368 0.626 
Cells transfected with 
pshNS5-1 






Cells transfected with 
pshNS5scrambled-1 
0.037 -0.023 0.014 0.009 0.030 
 
c) Cells transiently-transfected with pshCapsid, pshNS2B and pshNS4B 
 1st Expt 2nd Expt 3rd Expt Average Standard 
Deviation 
Cells transfected with 
pshCapsid 
2.000 2.322 1.962 2.094 0.197 
Cells transfected with 
pshCapsidscrambled 
-0.026 0.191 0.041 0.068 0.111 
Cells transfected with 
pshNS2B 
2.425 2.208 2.485 2.373 0.145 
Cells transfected with 
pshNS2Bscrambled 






Cells transfected with 
pshNS4B 
1.057 1.419 1.650 1.375 0.298 
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 Cells transfected with 
pshNS4Bscrambled 
0.204 0.176 0041 0.140 0.086 
Cells transfected with 
pshCapsid 
1.638 1.903 2.066 1.889 0.216 
Cells transfected with 
pshCapsidscrambled 
0.096 0.096 0.146 0.113 0.028 
Cells transfected with 
pshNS2B 
1.602 2.022 1.909 1.844 0.217 
Cells transfected with 
pshNS2Bscrambled 
0.045 0.187 -0.084 0.0495 0.135 
Cells transfected with 
pshNS4B 






Cells transfected with 
pshNS4Bscrambled 
-0.079 -0.791 -0.0843 -0.080 0.002 
 
C) Cells stably-transfected with pshCapsid, pshNS2B, pshNS4B and pshNS5. 
 1st Expt 2nd Expt 3rd Expt Average Standard 
Deviation 
Cells transfected with 
pshCapsid 
3.269 3.230 3.30 3.266 0.035 
Cells transfected with 
pshCapsidscrambled 
-0.051 0.184 0.113 0.082 0.120 
Cells transfected with 
pshNS2B 
2.506 1.939 2.255 2.233 0.284 
Cells transfected with 
pshNS2Bscrambled 






Cells transfected with 
pshNS4B 
1.026 1.342 1.325 1.231 0.177 
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Cells transfected with 
pshNS4Bscrambled 
0.084 0.087 -0.096 0.024 0.105 
Cells transfected with 
pshNS5 
0.550 1.277 1.491 1.106 0.493 
 
Cells transfected with 
pshNS5scrambled 
0.041 0.301 0.491 0.277 0.225 
Cells transfected with 
pshCapsid 
3.985 3.455 3.544 3.661 0.283 
Cells transfected with 
pshCapsidscrambled 
-0.069 -0.146 -0.131 -0.115 0.040 
Cells transfected with 
pshNS2B 
2.610 2.070 2.508 2.396 0.286 
Cells transfected with 
pshNS2Bscrambled 
-0.197 0.124 -0.176 -0.082 0.180 
Cells transfected with 
pshNS4B 
0.221 1.037 0.115 0.458 0.504 
Cells transfected with 
pshNS4Bscrambled 
-0.193 -0.096 -0.176 -0.155 0.051 
Cells transfected with 
pshNS5 






Cells transfected with 
pshNS5scrambled 
0.037 0.477 -0.083 0.143 0.294 
 
 
 
